

# P2 Receptors for Extracellular Nucleotides in the Central Nervous System: Role of P2X7 and P2Y<sub>2</sub> Receptor Interactions in Neuroinflammation

Gary A. Weisman · Jean M. Camden ·  
Troy S. Peterson · Deepa Ajit · Lucas T. Woods ·  
Laurie Erb

Received: 3 February 2012 / Accepted: 21 March 2012 / Published online: 1 April 2012  
© Springer Science+Business Media, LLC 2012

**Abstract** Extracellular nucleotides induce cellular responses in the central nervous system (CNS) through the activation of ionotropic P2X and metabotropic P2Y nucleotide receptors. Activation of these receptors regulates a wide range of physiological and pathological processes. In this review, we present an overview of the current literature regarding P2X and P2Y receptors in the CNS with a focus on the contribution of P2X7 and P2Y<sub>2</sub> receptor-mediated responses to neuroinflammatory and neuroprotective mechanisms.

**Keywords** P2Y<sub>2</sub> receptor · P2X7 receptor ·  
Neuroprotection · Neuroinflammation

## Introduction

Extracellular nucleotides, such as adenosine 5'-triphosphate (ATP) and uridine 5'-triphosphate (UTP), are released from cells under a variety of physiological and pathological conditions whereupon they activate P2 nucleotide receptors on

the surface of neighboring cells [1, 2]. P2 receptors are a diverse family of plasma membrane proteins that can be segregated into two subtypes: the P2X receptors that are ATP-selective cation channels and the P2Y receptors for ATP, UTP, or their metabolites that are coupled to heterotrimeric G proteins [3, 4]. To date, genes for seven P2X receptors and eight P2Y receptors have been cloned and their protein products have been extensively characterized in a variety of cell and tissue types [5, 6]. In the central nervous system (CNS), multiple P2X and P2Y receptor subtypes are expressed in neurons, glial cells, oligodendrocytes, macrophages, and endothelium where they regulate physiological responses, including neurotransmission, pain perception, phagocytosis, and maintenance of the blood–brain barrier [7–9]. Pathophysiological responses are also regulated by P2X and P2Y receptors, including the propagation of inflammation due to the release of nucleotide agonists from damaged or diseased cells [10–12]. This review describes the contributions of both P2X and P2Y receptors to cell specific functions in the CNS and focuses on the dual roles of the ionotropic P2X7 receptor (P2X7R) for ATP and the G protein-coupled P2Y<sub>2</sub> receptor (P2Y<sub>2</sub>R) for ATP and UTP in the regulation of proinflammatory responses in the brain. Recent studies have found that the release of extracellular ATP from stressed or damaged cells of the CNS can activate microglial cell P2X7Rs, which increases cytokine release, e.g., interleukin-1 $\beta$  (IL-1 $\beta$ ), and the phagocytic activity of microglial cells [13]. Additionally, IL-1 $\beta$  has been shown to upregulate P2Y<sub>2</sub>R expression in neurons to promote neuroprotective responses [14]. These findings are reviewed in this paper and suggest that both P2X7 and P2Y<sub>2</sub> receptors are promising targets for the treatment of neurodegenerative and other inflammatory diseases.

---

G. A. Weisman (✉) · J. M. Camden · D. Ajit · L. T. Woods ·  
L. Erb  
Department of Biochemistry, University of Missouri,  
540E Life Sciences Center, 1201 Rollins Road,  
Columbia, MO 65211-7310, USA  
e-mail: weismang@missouri.edu

G. A. Weisman · T. S. Peterson  
Interdisciplinary Neuroscience Program, University of Missouri,  
Columbia, MO, USA

G. A. Weisman · J. M. Camden · T. S. Peterson · D. Ajit ·  
L. T. Woods · L. Erb  
Christopher S. Bond Life Sciences Center, University of Missouri,  
Columbia, MO, USA


## P2X Receptors in the Central Nervous System

P2X receptors (P2XRs) are ligand-gated, nonselective cation channels activated by extracellular ATP. Seven pharmacologically distinct P2XR subtypes have been identified, i.e., P2X1–P2X7, and shown to be activated by ATP and its analogues [15, 16]. P2XRs range from 379 to 595 amino acids in length and, as shown in Fig. 1, consist of two transmembrane domains, a large extracellular loop, and intracellular N- and C-termini [17]. P2XRs share ~50 % sequence homology with one third of the extracellular loop conserved, suggesting an ATP binding site [18]. P2X1 and P2X3 receptors rapidly desensitize (within milliseconds), whereas P2X2, P2X5, P2X6, and P2X7 receptors desensitize slowly (within seconds) upon activation by ATP [19]. Depending on the subtype, P2XR subunits interact in a variety of homo- or heteromeric forms to regulate a wide range of cellular responses in the CNS under physiological and pathological conditions [20, 21]. The distribution of P2XR subtypes in the CNS is dependent upon species, brain region, and cell type [22–30]. The P2X2R, P2X4R, and P2X6R appear to be abundantly expressed throughout the brain, whereas the remaining subtypes are expressed in distinct regions [22, 24, 31]. In neurons, activation of P2XRs by extracellular ATP has been reported to have both presynaptic and postsynaptic effects including the modulation of transmembrane currents and neurotransmitter release

[32–37]. All types of glia, e.g., astrocytes, oligodendrocytes, Schwann cells, and microglial cells express P2XRs where they can regulate inflammatory, neurodegenerative, and neuroprotective responses [37]. Most notably, the P2X7R has gained recognition for its possible role in neurodegenerative disorders [38, 39]. The function of the CNS is dependent on neuronal–glial interactions, and the complexity of P2XR signaling in both cell types adds to the difficulty in interpreting ATP-mediated events *in vivo*. The cell and tissue distribution and functional relevance of homomeric and heteromeric P2X receptors in the nervous system are summarized in Table 1.

P2X1Rs have been shown to cause contraction of neurogenic smooth muscle [40, 41], platelet activation [42, 43], and neuronal [33, 44] and glial cell responses [45]. Among the P2XRs, the P2X1R has the highest affinity for ATP ( $EC_{50}$  ~1  $\mu$ M) [46]. The P2X1R is often observed in a heteromeric complex with the P2X2R and P2X5R resulting in biophysical and pharmacological properties distinct from those observed when each of these receptor subtypes is expressed separately [47–52]. In superior cervical ganglia neurons, the P2X1R contributes to ATP-mediated responses by forming a heteromeric unit with the P2X2R [44], whereas ATP-evoked biphasic membrane currents in mouse cortical astrocytes are regulated by P2X1R/P2X5R heteromeric channels [45].

P2X2Rs are widely expressed in the CNS with predominant expression in the cerebral cortex, cerebellum, striatum,



**Fig. 1** Structural features of P2X and P2Y receptors. Based on structure and function, P2 nucleotide receptors can be divided into two classes. The P2X receptors are nonselective ligand-gated cation channels featuring two transmembrane domains and a large extracellular loop. P2X receptors interact in a wide variety of homo- and heteromeric forms depending on tissue-specific expression and receptor subtype (i.e., P2X1–7) and they are activated by extracellular ATP. The P2X7R has received much attention due to its capacity for intracellular signaling via a large C-terminal tail and its participation in inflammatory processes. The P2YRs are classical G

protein-coupled receptors featuring an extracellular N-terminus, seven transmembrane domains, and an intracellular C-terminus that is structurally diverse between P2Y receptor subtypes. The  $G_q$ -coupled P2Y<sub>1,2,4,6,11</sub> and the  $G_i$ -coupled P2Y<sub>12,13,14</sub> receptors are activated by adenine and uridine tri- and dinucleotides with pharmacologically distinct efficacies and potencies. The P2Y<sub>2</sub>R subtype has been shown to associate with integrins via an extracellular RGD domain and to transactivate growth factor receptors via the binding of Src to Src-homology-3 (SH3) domains located within the C-terminus. Asterisk only present in the P2Y<sub>2</sub> receptor

**Table 1** P2X receptors in the nervous system

Receptor subtype	Expression		Function
	Cell type	Region	
Homomeric			
P2X1	Neurons, astrocytes, microglia	Cerebral cortex, superior cervical ganglia	Neurogenic smooth muscle contraction, platelet activation, neuron and glial responses
P2X2	Neurons, astrocytes	Cerebral cortex, cerebellum, hippocampus, striatum, habenula, substantia nigra, dorsal root ganglia, mesenteric ganglia	Nociceptive transmission, hyperalgesia, allodynia, pre- and postnatal neurogenesis
P2X3	Neurons	Dorsal root ganglia, spinal cord	Enhance glutamate and substance P release, neuropathic pain sensation
P2X4	Neurons, astrocytes, microglia	Cerebellum, hippocampus, brainstem, spinal cord	Release of brain-derived neurotrophic factor, induce neuropathic pain, prostaglandin E2 release, synaptic strengthening, hypersensitivity to sensory stimuli
P2X5	Neurons	Cerebral cortex, cerebellum, hippocampus, hypothalamus, thalamus, olfactory bulb, globus pallidum, midbrain, and hindbrain	Interconnection of cortical areas, postsynaptic purinergic transmission
P2X6	Neurons, astrocytes	Cerebellum, hippocampus, purkinje neurons, pyramidal neurons, sensory ganglia	Rarely forms functional homomeric receptors
P2X7	Neurons, astrocytes, microglia	Cerebral cortex, hippocampus, brainstem, nucleus accumbens, spinal cord	Release of proinflammatory cytokines, apoptosis, membrane pore formation, glutamate release, ATP release, induction of synaptic plasticity
Heteromeric			
P2X1/P2X2	Neurons	Superior cervical ganglia	ATP-mediated physiological responses
P2X1/P2X5	Astrocytes	Cerebral cortex	ATP-evoked membrane currents
P2X2/P2X3	Neurons	Dorsal root ganglia	Similar to P2X3, but with reduced desensitization
P2X2/P2X6	Neurons	Dogiel type II neurons in myenteric plexus	ATP-mediated physiological responses

The expression and function of P2X receptor subtypes in the nervous system are summarized. This table highlights the information presented in this review article and is not considered to be comprehensive

hippocampus, habenula, substantia nigra, dorsal ganglia neurons, mesenteric ganglia neurons, and glial cells [23, 24, 53–57]. The P2X2R is distinguished from other members of the P2XR family, since multiple splice variants exist in different mammalian species with diverse functional properties [58]. Many studies have shown that P2X2Rs play a role in nociceptive transmission, hyperalgesia, and allodynia, particularly when present as functional heterotrimers with P2X3Rs [56, 59, 60]. The pharmacological properties of P2X2R/P2X3R are similar to the P2X3R, but the desensitization rate of the P2X3R is reduced by its interaction with the P2X2R [61]. P2X2Rs and P2X2R/P2X3R have been implicated in pain processing [62]; however, with chronic pain, their functions are altered by the action of other P2XRs, especially those expressed in immune cells, such as microglia [63]. In addition to interactions with P2X2Rs, P2X3Rs also form homotrimeric receptors that are prominently expressed in primary sensory neurons where they enhance the release of glutamate and substance P [32, 64–66], which contribute to both acute and chronic pain sensation [60]. In vivo studies using P2X2R<sup>-/-</sup>,

P2X3R<sup>-/-</sup>, and P2X2R<sup>-/-</sup>/P2X3R<sup>-/-</sup> mice have contributed significantly to our understanding of neuropathic and inflammatory pain sensation and have led to the development of therapeutic antagonists to these receptors [67, 68]. The P2X2R also has been suggested to play a role in pre- and postnatal neurogenesis [69].

The P2X4R is expressed throughout the central and peripheral nervous systems [29, 44, 70–72]. The P2X4R is upregulated in activated microglial cells after spinal cord or peripheral nerve injury where it appears to mediate the release of brain-derived neurotrophic factor and induce neuropathic pain [73]. Recent studies provide evidence that the functional expression of P2X4Rs in tissue-resident macrophages regulates inflammation-dependent prostaglandin E2 release [74]. Activation of homomeric P2X4Rs in hippocampal neurons has been suggested to contribute to synaptic strengthening and hypersensitivity to sensory stimuli [72, 75]. In addition, hippocampal synaptic transmission and long-term potentiation were abolished in P2X4R<sup>-/-</sup> mice [76]. A unique characteristic of the P2X4R is its modulation by trace metals; copper inhibits whereas zinc and cobalt

potentiate P2X4R activity [58]. P2X4R activity has been shown to be modulated by the allosteric effector ivermectin [58]. Heteromeric assembly of the P2X4R with the P2X1, P2X6, and P2X7 receptor subtypes has been described [77–79], although the functional relevance of these complexes in vivo is currently unknown.

The expression of the P2X5R subtype in the mouse CNS is most abundant in the olfactory bulb, cerebral cortex, globus pallidum, hippocampus, thalamus, hypothalamus, cerebellar cortex, and mid- and hindbrain nuclei [80]. Although in vitro data have demonstrated ATP-evoked currents coupled to P2X5R activation, little is known about the physiological relevance of P2X5Rs in the CNS. Guo et al. speculate that P2X5R expression in the molecular layer of the cerebral cortex could play a role in interconnection of local cortical areas and P2X5R expression in the olfactory bulb suggests a role in fast excitatory postsynaptic purinergic transmission [81]. In vitro studies have shown that activation of the homomeric P2X5R results in small, non-desensitizing currents, whereas activation of frequently observed heteromeric P2X5/P2X1 receptors results in slowly desensitizing ATP-evoked currents [48, 50]. A P2X5R<sup>-/-</sup> mouse has not yet been developed; however, it will be critical for evaluating the role of the P2X5R in vivo. Interestingly, a recent study indicates that most humans express only a nonfunctional isoform of the P2X5R [82].

In the CNS, the P2X6R is expressed in Purkinje cells in the cerebellum, pyramidal cells in the hippocampus, and sensory ganglia [22, 29, 83–85]. The ability of the P2X6R to form functional homomeric receptors is very low due to inefficient glycosylation of the N-terminus [86, 87]. P2X6Rs readily form functional heteromers with P2X2 and P2X4 receptors, where activation of one subtype potentiates the activity of the other [88]. In the myenteric plexus, the P2X6R is expressed in Dogiel type II neurons where it likely regulates physiological responses to ATP as a heteromeric complex with P2X2Rs [89].

Among the P2X receptor subtypes, the P2X7 receptor has gained prominent recognition as a regulator of inflammatory responses [90]. P2X7Rs are expressed in many types of cells, notably in immune cells where activation by ATP increases the release of proinflammatory cytokines and apoptotic cell death [91, 92]. The P2X7R was first cloned from rat brain [93] and, subsequently, has been found to be expressed in microglia, neurons, and astrocytes [39, 92, 94, 95]. The P2X7R requires high concentrations of ATP (>0.1 mM) for activation, although the photoaffinity ligand BzATP is a more potent agonist [96, 97]. Stimulation of the P2X7R regulates the gating of nonselective cation channels, mitochondrial and plasma membrane depolarization, the formation of plasma membrane pores, plasma membrane blebbing, and the production of reactive oxygen species (ROS), responses ultimately leading to cell death [10, 90,

97–103]. P2X7R activity is dramatically potentiated by decreasing the divalent cation concentration, indicating that ATP<sup>4+</sup> may be the active ligand [104–106]. P2X7Rs have been shown to mediate the release of neurotransmitters, e.g., glutamate, GABA, and ATP, and may be required for the induction of synaptic plasticity [38, 107, 108]. It also has been shown that P2X7R activation induces hypoxia- and caspase-dependent neuronal cell death [109, 110]. Activation of P2X7Rs in glial cells results in the release of the proinflammatory cytokines TNF $\alpha$ , IL-1 $\beta$ , and leukotrienes, thereby triggering or potentiating neuroinflammation [111–114], as described below. The P2X7R is upregulated in damaged nerves [115, 116] and in nerves obtained from neuropathic pain patients [117]. In a mouse model of neuropathic pain, hypersensitivity to pain stimuli was completely absent upon deletion of the P2X7R [117]. The P2X7R is also upregulated in microglia around  $\beta$ -amyloid plaques in a mouse model of Alzheimer's disease (AD) where it mediates superoxide production [118]. Enhanced expression of P2X7Rs also was observed in microglia derived from post-mortem AD brains compared with glia obtained from non-demented brains [119]. Furthermore, studies with a mouse model of Huntington's disease suggest that P2X7Rs may play a role in disease pathogenesis [120]. Therefore, the P2X7R receptor could represent a therapeutic target for treating neurodegenerative diseases.

## P2Y Receptors in the Central Nervous System

P2Y receptors (P2YRs) are classical heterotrimeric G protein-coupled seven-pass transmembrane receptors, as shown in Fig. 1. The extracellular N-terminus contains several potential glycosylation sites, and the C-terminus contains consensus phosphorylation sites for protein kinases [121–124]. The intracellular loops and C-terminus have structural diversity among P2YR subtypes, thereby influencing the degree of coupling with G<sub>q/11</sub>, G<sub>s</sub>, and G<sub>i</sub> proteins [125]. The length of human P2YRs varies from 328 (P2Y<sub>6</sub>R) to 377 (P2Y<sub>2</sub>R) amino acids, and the composition reveals two structurally distinct subgroups within the P2YR family, the G<sub>q</sub>-coupled P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, and P2Y<sub>11</sub> receptors and the G<sub>i</sub>-coupled P2Y<sub>12</sub>, P2Y<sub>13</sub>, and P2Y<sub>14</sub> receptors [125, 126]. The degree of sequence homology among members of the human P2YR family ranges from 20 to 50 %, suggesting a relatively high functional diversity [127]. It has been demonstrated that positively charged amino acids within transmembrane domains of P2YRs contribute to agonist binding [122, 128, 129]. P2YRs, whose agonists are adenine and/or uridine nucleotides, are expressed in many cell types comprising the CNS and have been shown to regulate neurotransmission, inflammation, cell growth, and apoptosis [130–133]. P2Y<sub>1</sub>, P2Y<sub>12</sub>,

P2Y<sub>13</sub>, and P2Y<sub>14</sub> receptors are activated by adenine nucleotides only, whereas the P2Y<sub>2</sub>R and rodent P2Y<sub>4</sub>R can be activated by either adenine or uridine nucleotides and the human P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors are selective for uridine nucleotides [125]. The P2Y<sub>14</sub>R subtype is activated by uridine 5'-diphosphate (UDP)-glucose [6, 84, 125]. All eight P2Y receptor subtypes are expressed in primary rat astrocytes or astrocytoma cells [125, 134–136], although the expression patterns vary with age [137, 138]. Rodent neurons express P2Y<sub>1,2,4,6,12,13</sub> receptors [14, 139, 140]. P2YRs are expressed at postsynaptic terminals where P2Y<sub>1</sub>, P2Y<sub>2</sub>, and P2Y<sub>4</sub> receptors are neuromodulators that have inhibitory roles in synaptic transmission [34, 141–143]. The cell and tissue distribution, agonist specificities, and functional relevance of P2Y receptors in the nervous system are summarized in Table 2.

The P2Y<sub>1</sub>R has a widespread distribution in mammalian brain, including the cerebral cortex, hippocampus, caudate

nucleus, putamen, globus pallidus, habenula, subthalamic nucleus, midbrain, and cerebellum, as demonstrated in autoradiographic and immunohistochemical studies [144–146]. The P2Y<sub>1</sub>R is intensely expressed in Purkinje cells, in deep layers of the cerebral cortex, and in areas of the hippocampus sensitive to ischemia [146]. P2Y<sub>1</sub>R immunoreactivity has also been observed in oligodendrocytes and astrocytes in brain white matter tracts and optic nerves [134, 147]. P2Y<sub>1</sub>Rs have been suggested to play important roles in glial cell functions [146]. P2Y<sub>1</sub>R activation in astrocytes of hippocampal cultures has been suggested to provide neuroprotection from oxidative stress by increasing IL-6 release [148]. P2Y<sub>1</sub>Rs are also expressed in microglial cells [116, 134, 144, 149, 150], rat neuroprogenitor cells [151], and various sensory neurons such as dorsal root ganglia and dorsal horn neurons [152–154]. Studies have suggested potential roles for P2Y<sub>1</sub>Rs in brain development and repair [151] and sensory reception [153, 155].

**Table 2** P2Y receptors in the nervous system


Receptor subtype	Agonist	Expression		Function
		Cell type	Region	
P2Y <sub>1</sub>	ADP, ATP	Neurons, astrocytes, microglia, oligodendrocytes	Cerebral cortex, cerebellum, hippocampus, midbrain, caudate nucleus, putamen, globus pallidus, habenula, subthalamic nucleus, dorsal root ganglia, dorsal horn	Synaptic transmission modulation, provides neuroprotection by stimulating IL-6 release from astrocytes, brain development and repair, sensory reception
P2Y <sub>2</sub>	ATP, UTP	Neurons, astrocytes, microglia	Cerebral cortex, cerebellum, hippocampus, nucleus accumbens, spinal cord	Promote neurite outgrowth, stimulate $\alpha$ -secretase-dependent processing of amyloid precursor protein, increase phagocytosis of A $\beta$ peptide, regulate intracellular calcium waves, stimulate proliferation, modulate pain sensation, increase cell motility
P2Y <sub>4</sub>	ATP, UTP	Neurons, astrocytes, microglia	Cerebral cortex, hippocampus	Synaptic transmission modulation, regulation of blood–brain barrier function, blood flow, metabolic trafficking, water homeostasis
P2Y <sub>6</sub>	UDP, UTP	Neurons, astrocytes, microglia	Cerebral cortex, cerebellum, hippocampus, amygdala, cingulate gyrus, putamen, nucleus accumbens, superior cervical ganglia, dorsal root ganglia	Stimulate phagocytic activity, neuroinflammatory responses
P2Y <sub>11</sub>	ATP, ADP	Neurons	Cerebellum, hippocampus, parahippocampal gyrus, putamen, striatum, nucleus accumbens	Neuroinflammatory responses
P2Y <sub>12</sub>	ADP	Neurons, astrocytes, microglia, oligodendrocytes	Cerebral cortex, cerebellum, hippocampus, nucleus accumbens	Regulation of migration and chemotaxis
P2Y <sub>13</sub>	ADP	Neurons, astrocytes	Brainstem	Modulation of synaptic transmission, modulates expression of cell survival genes
P2Y <sub>14</sub>	UDP-glucose	Astrocytes, microglia	Cerebral cortex, cerebellum	Modulation of immune system's anti-tumor response

The agonists, expression, and function of P2Y receptor subtypes in the nervous system are summarized. This table highlights the information presented in this review article and is not considered to be comprehensive



The contribution of the P2Y<sub>2</sub>R subtype to CNS functions is becoming better understood [9, 156, 157] and appears to be most relevant under pathophysiological conditions, such as inflammation and bacterial infection [9, 158]. The mammalian P2Y<sub>2</sub>R is equipotently activated by ATP or UTP [7, 125] and is upregulated in many cell and animal models of inflammation or injury [14, 159–163], including acute and chronic stages of spinal cord injury [164], brain ischemia, mechanical injury to the nucleus accumbens, and brain trauma [116, 165], suggesting that P2Y<sub>2</sub>R upregulation represents a cellular response to tissue damage and inflammation. P2Y<sub>2</sub>R expression under proinflammatory conditions is regulated by NF- $\kappa$ B binding to the P2Y<sub>2</sub>R promoter [166], consistent with the established role of NF- $\kappa$ B activation in the induction of inflammation [167]. In addition to the typical G<sub>q</sub>-coupled activation of the PLC/IP<sub>3</sub>/PKC pathway, the P2Y<sub>2</sub>R has a variety of structural motifs that enable it to activate integrin and growth factor receptor signaling cascades, as shown in Fig. 2. For example, P2Y<sub>2</sub>R activation by ATP or UTP has

been shown to induce phosphorylation of growth factor receptors which increases the activities of the MAP kinases ERK1/2 and the related adhesion focal tyrosine kinase (RAFTK) via a pathway dependent upon Src and Shc/Grb2 [168–170]. However, other studies show that P2Y<sub>2</sub>R-mediated epidermal growth factor receptor (EGFR) phosphorylation is Src-independent, but requires the release of growth factors via P2Y<sub>2</sub>R-dependent activation of the matrix metalloproteases ADAM10 and ADAM17 [171]. These differences appear to be due to cell type, e.g., endothelial vs. epithelial. The P2Y<sub>2</sub>R is unique among GPCRs in that it contains the consensus integrin-binding motif Arg-Gly-Asp (RGD) in a putative extracellular domain that enables the association of the P2Y<sub>2</sub>R with  $\alpha_v\beta_{3/5}$  integrins allowing activation of heterotrimeric G<sub>o</sub> and G<sub>12</sub> proteins that regulate the activities of the small GTPases Rho and Rac [172–174], regulators of actin polymerization and cytoskeletal rearrangements required for cell migration [175, 176]. In addition, the P2Y<sub>2</sub>R contains SH3-binding motifs in its C-terminal domain that can interact with



**Fig. 2** P2Y<sub>2</sub>R signaling pathways. The P2Y<sub>2</sub>R modulates a variety of cellular processes through classical G protein-coupled receptor pathways and unique receptor motifs. Activation of the P2Y<sub>2</sub>R by ATP or UTP stimulates the G<sub>q</sub>-dependent activation of PLC leading to the generation of IP<sub>3</sub> and DAG. IP<sub>3</sub> triggers a release of Ca<sup>2+</sup> from intracellular stores leading to an increase in [Ca<sup>2+</sup>]<sub>i</sub> and the activation of Ca<sup>2+</sup>-dependent proteins, whereas DAG serves to activate PKC leading to activation of a variety of downstream proteins including RAFTK (also known as Pyk2) and the MAP kinases ERK1/2. The Src-homology-3 (SH3) domains in the C-terminus allow the P2Y<sub>2</sub>R to stimulate Src-dependent transactivation of growth factor receptors and their downstream signaling molecules Shc and Grb2 leading to ERK1/2 and p38 activation of cell proliferation and neurite outgrowth. The P2Y<sub>2</sub>R also has been shown to upregulate

VCAM-1 through a pathway involving VEGFR-2. Furthermore, P2Y<sub>2</sub>R activation has been shown to stimulate the PI3K/Akt pathway to inhibit apoptosis in neurons, a response that was dependent on Src activation. SH3 domains also allow the P2Y<sub>2</sub>R to interact with the actin cytoskeleton via the actin-binding protein filamin A (FlnA). Alternatively, the P2Y<sub>2</sub>R can access the actin cytoskeleton through an extracellular RGD domain that interacts with  $\alpha_v\beta_{3/5}$  integrins to enable activation of G<sub>o</sub> and G<sub>12</sub> proteins allowing the P2Y<sub>2</sub>R to stimulate cell migration, phagocytosis, neurite outgrowth, and diapedesis by activating the cytoskeletal regulators Rac and Rho. Lastly, the P2Y<sub>2</sub>R is able to activate the matrix metalloproteases ADAM10 and ADAM17 to induce non-amyloidogenic APP processing and shedding of growth factors

the actin-binding protein filamin A (FLNa), another known regulator of cytoskeletal rearrangements, suggesting that the P2Y<sub>2</sub>R may regulate migration of cells by both RGD-dependent interactions with integrins and C-terminal-dependent association with actin-binding proteins [177]. Moreover, the P2Y<sub>2</sub>R has been reported to regulate migration of some cell types via transactivation of growth factor receptors [173, 178], suggesting that a complex array of signaling events uniquely coupled to P2Y<sub>2</sub>R activation may be required to optimize the cytoskeletal rearrangements whereby the P2Y<sub>2</sub>R regulates cell-specific functions, e.g., neurite outgrowth, phagocytosis, synapse formation, and chemokinesis.

P2Y<sub>2</sub>R expression in rat primary cortical neurons is upregulated in response to IL-1 $\beta$  [14], a cytokine whose levels are elevated in the brains of AD patients [179, 180]. Subsequent activation of these upregulated P2Y<sub>2</sub>Rs in neurons promotes neurite outgrowth [181] and generates the non-amyloidogenic soluble APP $\alpha$  peptide, rather than neurotoxic A $\beta$ <sub>1–42</sub> peptide aggregates associated with AD [14]. In mouse primary microglial cells, the P2Y<sub>2</sub>R is upregulated in the presence of A $\beta$ <sub>1–42</sub> and when activated can increase the phagocytosis and degradation of neurotoxic forms of A $\beta$  [9, 182, 183]. In astrocytic cells, the P2Y<sub>2</sub>R has been suggested to contribute to synaptic transmission through the regulation of intracellular calcium waves [184] and upregulates anti-apoptotic protein expression to promote cell survival [185]. Thus, P2Y<sub>2</sub>R upregulation in response to proinflammatory conditions likely serves a neuroprotective role in the CNS that requires contributions from both glial and neuronal P2Y<sub>2</sub>Rs, as described in more detail below.

The human P2Y<sub>4</sub>R is preferentially activated by uridine nucleotides, whereas the rat and mouse P2Y<sub>4</sub>Rs are stimulated equipotently by ATP and UTP [186–188]. P2Y<sub>4</sub>R mRNA is highly expressed in human brain [189]. Single cell RT-PCR demonstrated the expression of P2Y<sub>4</sub>Rs in rat hippocampal pyramidal neurons [34]. The expression of P2Y<sub>4</sub>Rs in astrocytes and microglial cells has been extensively documented [134, 137, 150, 186]. P2Y<sub>4</sub>Rs, as well as P2Y<sub>2</sub>Rs, are strongly expressed in glial endfeet in proximity to blood vessel walls [190] where their activation by ATP has been postulated to regulate blood–brain barrier function, blood flow, metabolic trafficking, and water homeostasis [190, 191].

The P2Y<sub>6</sub>R is activated by UDP and to a lesser extent UTP [192]. In 18 areas of the human brain, the level of P2Y<sub>6</sub>R mRNA expression was highest in the amygdala, cingulate gyrus, nucleus accumbens, and putamen [189]. Single cell RT-PCR revealed P2Y<sub>6</sub>R mRNA in 2 of 12 pyramidal neurons of rat hippocampus [34]. In addition, P2Y<sub>6</sub>R mRNA has been demonstrated in superior cervical ganglion [44, 193] and dorsal root ganglion neurons [152, 153]. Functional studies have revealed the presence of P2Y<sub>6</sub>R activity in cerebellar and cortical astrocytes [134,

194]. P2Y<sub>6</sub>R activation has been shown to increase phagocytotic activity of microglia, postulated to occur in vivo in response to UTP released from damaged cells [195, 196]. Consistent with this hypothesis, injury has been shown to induce increased P2Y<sub>6</sub>R expression in astroglial cells [165]. In microglial cells stimulated overnight with bacterial lipopolysaccharide, P2Y<sub>6</sub>R-mediated increases in the intracellular calcium concentration were observed, suggesting a role for the P2Y<sub>6</sub>R in neuroinflammation [150].

The P2Y<sub>11</sub>R can couple to multiple G proteins to regulate the activity of two second messenger systems: adenylate cyclase-mediated cAMP production and PLC-dependent production of IP<sub>3</sub> and DAG that modulate calcium release from intracellular storage sites and protein kinase C activation, respectively [197]. The P2Y<sub>11</sub>R is activated by ATP or ADP, but not by uridine nucleotides [197]. P2Y<sub>11</sub>R mRNA expression is prominent in nucleus accumbens, parahippocampal gyrus, putamen, and striatum [84]. The P2Y<sub>11</sub>R has been localized to single rat hippocampal pyramidal neurons and to Purkinje cells in adult rat cerebellum [34, 198]. Inhibition of the P2Y<sub>11</sub>R has been shown to delay ATP-induced neutrophil apoptosis, suggesting a role for the P2Y<sub>11</sub>R in the regulation of neuroinflammatory responses [199].

The P2Y<sub>12</sub>R is widely distributed in the brain with a pattern consistent with expression in astrocytes [200, 201]. RT-PCR has demonstrated the presence of P2Y<sub>12</sub>R mRNA in single rat hippocampal pyramidal neurons [34]. Cortical and cerebellar astrocytes and astrocytes in the rat nucleus accumbens also express P2Y<sub>12</sub>Rs [134, 165, 202]. P2Y<sub>12</sub>Rs have been suggested to regulate the migration of microglial cells towards damaged neurons [203]. P2Y<sub>12</sub>R expression in microglia is robust in the “resting” state, but dramatically reduced in activated microglia, and P2Y<sub>12</sub>R<sup>−/−</sup> mice have significantly diminished directional branch extension toward sites of cortical damage in vivo [204]. In contrast, a recent study concludes that the expression of the P2Y<sub>12</sub>R in the CNS is restricted to oligodendrocytes [205]. It also has been suggested P2Y<sub>12</sub>Rs contribute to the migration and adhesion of glial cell processes to axons during premyelination [205].

The P2Y<sub>13</sub>R is activated by ADP [206] and 2-methylthio ADP is a potent synthetic agonist [207], similar to the P2Y<sub>12</sub>R; however, ATP and ATP analogues are inactive at the P2Y<sub>13</sub>R [208]. P2Y<sub>13</sub>R expression has been localized to brainstem astrocytes and glutamatergic neurons [145, 189, 209]. P2Y<sub>13</sub>Rs, along with P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors, have been shown to regulate Na<sup>+</sup> and Cl<sup>−</sup>-dependent synaptic glycinergic neurotransmitter transporters to increase transport of glycine from the synaptic cleft, thereby maintaining quantal glycine levels in inhibitory synaptic vesicles [209, 210]. The P2Y<sub>13</sub>R can also activate the glycogen synthase kinase-3 (GSK-3)-dependent phosphatidylinositol 3-kinase

(PI3K)/Akt survival pathway to increase translocation of the GSK-3 substrate  $\beta$ -catenin to the nucleus, where it modulates expression of cell survival genes [211].

The P2Y<sub>14</sub>R is expressed in astrocytes [189], and RT-PCR and single cell Ca<sup>2+</sup> imaging has documented the functional expression of P2Y<sub>14</sub>Rs in rat cortical and cerebellar astrocytes [134, 202]. Agonists of the P2Y<sub>14</sub>R include UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine, but not adenine or uridine nucleotides [212–214]. UDP-glucose has been shown to be released from a variety of cell lines, and UDP-glucose levels can exceed those of ATP under various conditions [215]. Functionally, P2Y<sub>14</sub>Rs in primary microglial cells from rat brain have been shown to modulate the calcium response to bacterial lipopolysaccharide [150]. P2Y<sub>14</sub>Rs expressed in immature dendritic cells have been suggested to play a role in the immune system's anti-tumor response [143, 216].

### Neuroinflammatory P2X7Rs Regulate Neuroprotective P2Y<sub>2</sub>R Expression

P2X7R activation contributes to neuroinflammation by promoting mitochondrial and plasma membrane depolarization, the formation of plasma membrane pores, plasma membrane blebbing, and the production of ROS [10, 90, 98–103]. In addition, P2X7R activation promotes neuroinflammation by causing the release of proinflammatory cytokines, such as IL-1 $\beta$  and TNF- $\alpha$  [90, 217, 218], and activation of MAP kinases and NF- $\kappa$ B, resulting in upregulation of proinflammatory gene products, including COX-2, chemokines, and cell adhesion molecules [90, 219–223] and the P2Y<sub>2</sub>R [166]. Importantly, P2X7R-mediated pore formation initially increases ATP release through P2X7R interactions with a pannexin hemi-channel in cells [91]. P2X7R-mediated IL-1 $\beta$  and ATP release is a mechanism whereby the P2X7R regulates functional P2Y<sub>2</sub>R expression in neurons and provides agonist for the activation of the upregulated P2Y<sub>2</sub>R and other P2 receptors [9]. ATP release also can occur from activated microglia and astrocytes in response to oxidative stress [9], following neuronal excitation [224, 225], via volume-activated anion channels [225], or upon exposure of cells to fibrillar or oligomeric forms of amyloidogenic A $\beta$ <sub>1–42</sub> peptides [157, 183, 226, 227]. Thus, P2X7 and P2Y<sub>2</sub> receptors may represent promising targets to control inflammatory responses associated with neurodegenerative diseases. Indeed, mice deficient in the P2X7R (P2X7R<sup>−/−</sup> mice) exhibit decreased inflammatory responses [117, 228–230], including a reduction in pulmonary fibrosis in a mouse model of lung inflammation [230] and the absence of pain hypersensitivity in mouse models of chronic inflammation and neuropathic pain [117]. Phase I and II clinical

trials for selective P2X7R antagonists are presently underway for the treatment of rheumatoid arthritis and other inflammatory diseases [231, 232].

Upregulation of the P2Y<sub>2</sub>R in response to P2X7R activation appears to promote neuroprotective responses. The ability of the P2Y<sub>2</sub>R to stimulate neuroprotective responses depends upon the coupling of the receptor to intracellular signaling pathways that are distinct among the P2YR family (see Fig. 2). These responses associated with P2Y<sub>2</sub>R upregulation include the outgrowth and stabilization of dendritic spines [9, 176, 233], which requires RGD-dependent P2Y<sub>2</sub>R/ $\alpha_v$  integrin interaction to stimulate Rac and Rho and induce cytoskeletal rearrangements [173, 174] and upregulation of neurofilament M and neurofilaments that promote neurite outgrowth [181]. P2Y<sub>2</sub>Rs also require Src to co-localize with the tyrosine receptor kinase A in the presence of nerve growth factor, a pathway that regulates neurite outgrowth and cell division via the activation of p38 and ERK1/2 MAP kinases [234, 235]. In neural progenitor cells isolated from the subventricular zone of adult mouse brain, P2Y<sub>2</sub>R activation was shown to induce proliferative responses such as the transient activation of the EGFR, the MAP kinases ERK1/2, and the transcription factor CREB [236]. Other studies indicate that the P2Y<sub>2</sub>R mediates the activation of PI3-kinase/Akt and MAP kinases to inhibit apoptosis of PC12 pheochromocytoma cells and dorsal root ganglion neurons [235, 237]. P2Y<sub>2</sub>R upregulation by IL-1 $\beta$  and subsequent activation in primary cortical neurons increases amyloid precursor protein (APP) processing via activation of matrix metalloproteases (i.e.,  $\alpha$ -secretases), a neuroprotective response that produces a non-amyloidogenic soluble APP peptide (i.e., sAPP $\alpha$ ) rather than neurotoxic amyloidogenic A $\beta$  peptide [14]. IL-1 $\beta$  is known to stimulate neuronal synthesis of APP and increase the release of neurotoxic A $\beta$ , which further enhances IL-1 $\beta$  production [238]. We postulate that upregulation of the P2Y<sub>2</sub>R induced by IL-1 $\beta$  in vivo counteracts the potential neurotoxic effects of IL-1 $\beta$ -dependent elevations in APP levels by promoting generation of non-toxic sAPP $\alpha$  instead of A $\beta$ . Thus, P2Y<sub>2</sub>R upregulation in the CNS may delay the progression of neurodegeneration associated with reactive gliosis and chronic inflammation in AD and other neurological disorders.


Glial cells, including astrocytes and microglia, play important neuroprotective roles. Astrocytes contribute to the maintenance of the blood–brain barrier (BBB) [239–241], which prevents invasion of pathogenic, neurotoxic substances into the brain from the circulation [242, 243]. Astrocytes also release neurotrophic factors that regulate neuronal survival and sprouting and supply energy substrates to neurons [244]. Astrocytes have been shown to release ATP under a variety of pathological conditions [245–247] and ATP levels are elevated sufficiently by inflammation in vivo to activate P2 nucleotide receptors [245]. P2Y<sub>2</sub>Rs are upregulated in reactive astrocytes of the rat cortex and nucleus accumbens



in response to mechanical injury [165] and have been suggested to enhance astrocyte survival [185, 248]. In addition, interactions between the P2Y<sub>2</sub>R and integrins have been demonstrated to regulate the migration of astrocytes [173, 174, 249]. It also has been shown that P2X<sub>7</sub>R activation increases the expression of P2Y<sub>2</sub>Rs in rat astrocytes [250] likely via P2X<sub>7</sub>R-mediated IL-1 $\beta$  release [112, 226, 242, 251–253].

Microglia have important immunoregulatory functions in the CNS. Injury or other insults to the CNS trigger transformation of quiescent microglia into activated phenotypes, i. e., phagocytic macrophages [254, 255]. Activated microglia have neuroprotective functions [255–259], although sustained activation can be neurotoxic [256, 260–262]. Microglial cell activation by proinflammatory cytokines has been shown to increase cell motility and proliferation [263], responses associated with reactive gliosis in neurodegenerative diseases. Adenine and uridine nucleotides have been shown to increase the motility of microglial cells [195, 204, 264] via activation of P2Y<sub>2</sub> and P2Y<sub>12</sub> receptors [204, 265] and ATP release can significantly increase microglial process extension towards a site of injury [266]. The

endogenous expression of P2Y<sub>2</sub>Rs has been reported in mouse microglia [267, 268] where they have been shown to regulate responses associated with reactive gliosis [7, 9, 165, 185, 248, 249]. For example, the P2Y<sub>2</sub>R agonists UTP and ATP released from apoptotic cells have been shown to induce migration of phagocytic cells [269], which presumably serves to enhance the clearance of cellular debris. Microglial cells exposed to A $\beta$  also have been shown to release ATP [226, 270]. Studies using peritoneal macrophages in mice have shown that stimulation of P2Y<sub>2</sub> and P2Y<sub>12</sub> receptors induces the formation of lamellipodia in membrane protrusions which is required for cell motility [271]. Co-activation of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors in human monocytes enhances migration, a response shown to involve toll-like receptor-induced IL-8 release [272, 273]. We have found that P2Y<sub>2</sub>R activation increases mouse microglial cell migration and phagocytic activity, such as the uptake of neurotoxic oligomeric A $\beta$ <sub>1–42</sub>, responses that are absent in microglia from P2Y<sub>2</sub>R<sup>−/−</sup> mice [183]. Both activated astrocytes and microglia internalize and degrade A $\beta$  [274–278], a pathway that reduces A $\beta$  toxicity in neurons that is postulated to play a role in the progression of AD. We speculate



**Fig. 3** P2X<sub>7</sub>R-mediated neuroinflammation stimulates P2Y<sub>2</sub>R-mediated neuroprotective responses. (1) ATP released under neuroinflammatory conditions can (2) activate the P2X<sub>7</sub>R to stimulate (3) the release of proinflammatory cytokines, including interleukin-1 $\beta$  (IL-1 $\beta$ ), and further ATP release via interaction of the P2X<sub>7</sub>R with pannexin hemi-channels. In response to the proinflammatory environment, quiescent microglia take on an (4a) activated phenotype and P2Y<sub>2</sub>R activation by extracellular ATP increases (5a) cell motility. In addition, (4b) IL-1 $\beta$  upregulates

P2Y<sub>2</sub>R expression in neurons and glia through NF- $\kappa$ B activation. (6) ATP release (from A $\beta$  exposure, cytokine exposure, oxidative stress, etc.) provides agonist for the (5b) P2Y<sub>2</sub>R to stimulate non-amyloidogenic APP processing and neurite outgrowth through P2Y<sub>2</sub>R interactions with matrix metalloproteases and the actin cytoskeleton, respectively. Another neuroprotective response to (7) P2Y<sub>2</sub>R activation in microglial cells is increased phagocytosis and degradation of neurotoxic oligomeric A $\beta$ <sub>1–42</sub>

that P2Y<sub>2</sub>Rs in glial cells contribute to the phagocytosis and degradation of neurotoxic forms of A $\beta$  in vivo under conditions where elevated levels of ATP release and IL-1 $\beta$  generation occur [279, 280].

Recent studies suggest that peripheral leukocytes and hematopoietic cells that differentiate into microglia have important functions in the CNS [281], particularly in response to tissue injury [282]. P2Y<sub>2</sub>Rs in endothelial cells that form the BBB may also regulate the migration of leukocytes across the BBB towards sites of injury or disease in the brain. Activation of the endothelial P2Y<sub>2</sub>R has been shown to enhance the diapedesis of neutrophils towards the chemoattractant lipopolysaccharide of gram-negative bacteria [273] through a mechanism involving Rho kinase activation, suggesting that P2Y<sub>2</sub>R associations with integrins may be involved [173, 174]. Microglia derived from bone marrow have been shown to phagocytose A $\beta$  deposits in the brain of AD mice to a greater extent than resident brain microglia [283]. Thus, diapedesis of microglia across the BBB, in addition to neurite outgrowth, non-amyloidogenic APP processing, and phagocytosis of neurotoxic forms of A $\beta$ , may comprise a neuroprotective phenotype linked to P2Y<sub>2</sub>R activation in several cell types that comprise the brain (i.e., neurons, glial cells, and endothelium). The neuroprotective pathways by which P2X<sub>7</sub>R-mediated upregulation and activation of P2Y<sub>2</sub>Rs are suggested to contribute to neuroprotection in the brain are shown in Fig. 3.

## Conclusion

This review summarizes data indicating that seven ionotropic P2X and eight G protein-coupled P2Y receptors for extracellular nucleotides are expressed in cell types comprising the CNS and these P2X and P2Y receptor subtypes have been shown to regulate diverse physiological and pathological responses under a variety of conditions. Recent studies indicate that activation of the P2X<sub>7</sub>R subtype during inflammation causes upregulation and activation of P2Y<sub>2</sub>Rs to promote neuroprotective responses. These findings suggest that ATP released from injured or stressed cells in the CNS can activate P2X<sub>7</sub>Rs in microglial cells to increase the release of proinflammatory cytokines, such as IL-1 $\beta$ , that increase the expression of the P2Y<sub>2</sub>R, particularly in neurons. Other studies indicate that both P2X<sub>7</sub>R and P2Y<sub>2</sub>R activation can increase phagocytosis of neurotoxic forms of A $\beta$  and that activation of the P2Y<sub>2</sub>R increases non-amyloidogenic APP processing, neuroprotective responses that are postulated to delay the onset or retard the progression of neurodegenerative diseases, such as Alzheimer's disease. In addition, P2Y<sub>2</sub>R activation in neurons has been shown to increase neurite outgrowth. The P2Y<sub>2</sub>R contains multiple motifs that enable its activation to directly couple

to integrin and growth factor receptor signaling pathways that play a role in cell proliferation and differentiation and cytoskeletal rearrangements that are critical for tissue repair. Thus, the studies described in this review suggest that the P2X<sub>7</sub>R and P2Y<sub>2</sub>R are promising targets for the treatment of neurodegenerative diseases.

## References

1. Burnstock G, Campbell G, Satchell D, Smythe A (1997) Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. 1970. *Br J Pharmacol* 120(4 Suppl):337–357, discussion 334–336
2. Heilbronn E, Knoblauch BH, Müller CE (1997) Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system. *Neurochem Res* 22(8):1041–1050
3. Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* 64(3):445–475
4. von Kügelgen I, Wetter A (2000) Molecular pharmacology of P2Y-receptors. *Naunyn Schmiedeberg's Arch Pharmacol* 362(4–5):310–323
5. Burnstock G, Kennedy C (1985) Is there a basis for distinguishing two types of P2-purinoceptor? *Gen Pharmacol* 16(5):433–440
6. Sak K, Webb TE (2002) A retrospective of recombinant P2Y receptor subtypes and their pharmacology. *Arch Biochem Biophys* 397(1):131–136. doi:10.1006/abbi.2001.2616
7. Weisman GA, Wang M, Kong Q, Chorna NE, Neary JT, Sun GY, Gonzalez FA, Seye CI, Erb L (2005) Molecular determinants of P2Y<sub>2</sub> nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. *Mol Neurobiol* 31(1–3):169–183
8. Gonzalez FA, Weisman GA, Erb L, Seye CI, Sun GY, Velazquez B, Hernandez-Perez M, Chorna NE (2005) Mechanisms for inhibition of P2 receptors signaling in neural cells. *Mol Neurobiol* 31(1–3):65–79. doi:10.1385/MN:31:1-3:065
9. Peterson TS, Camden JM, Wang Y, Seye CI, Wood WG, Sun GY, Erb L, Petris MJ, Weisman GA (2010) P2Y<sub>2</sub> nucleotide receptor-mediated responses in brain cells. *Mol Neurobiol* 41(2–3):356–366. doi:10.1007/s12035-010-8115-7
10. Bours MJ, Dagnelie PC, Giuliani AL, Wesselius A, Di Virgilio F (2011) P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation. *Front Biosci (Schol Ed)* 3:1443–1456
11. Ferrero ME (2011) Purinoceptors in inflammation: potential as anti-inflammatory therapeutic targets. *Front Biosci* 17:2172–2186
12. Fumagalli M, Lecca D, Abbracchio MP (2011) Role of purinergic signalling in neuro-immune cells and adult neural progenitors. *Front Biosci* 17:2326–2341
13. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, Verderio C (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. *J Immunol* 174(11):7268–7277
14. Kong Q, Peterson TS, Baker O, Stanley E, Camden J, Seye CI, Erb L, Simonyi A, Wood WG, Sun GY, Weisman GA (2009) Interleukin-1 $\beta$  enhances nucleotide-induced and  $\alpha$ -secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y<sub>2</sub> receptor. *J Neurochem* 109(5):1300–1310. doi:10.1111/j.1471-4159.2009.06048.x

15. MacKenzie AB, Surprenant A, North RA (1999) Functional and molecular diversity of purinergic ion channel receptors. *Ann N Y Acad Sci* 868:716–729
16. North RA, Surprenant A (2000) Pharmacology of cloned P2X receptors. *Annu Rev Pharmacol Toxicol* 40:563–580. doi:10.1146/annurev.pharmtox.40.1.563
17. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, Buell G (1994) A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. *Nature* 371(6497):516–519. doi:10.1038/371516a0
18. Vial C, Roberts JA, Evans RJ (2004) Molecular properties of ATP-gated P2X receptor ion channels. *Trends Pharmacol Sci* 25(9):487–493
19. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* 50(3):413–492
20. Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. *Nature* 442(7102):527–532. doi:10.1038/nature04886
21. Koles L, Furst S, Illes P (2007) Purine ionotropic (P2X) receptors. *Curr Pharm Des* 13(23):2368–2384
22. Collo G, North RA, Kawashima E, Merlo-Pich E, Neidhart S, Surprenant A, Buell G (1996) Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. *J Neurosci* 16(8):2495–2507
23. Vulchanova L, Arvidsson U, Riedl M, Wang J, Buell G, Surprenant A, North RA, Elde R (1996) Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. *Proc Natl Acad Sci U S A* 93(15):8063–8067
24. Kanjhan R, Housley GD, Burton LD, Christie DL, Kippenberger A, Thorne PR, Luo L, Ryan AF (1999) Distribution of the P2X2 receptor subunit of the ATP-gated ion channels in the rat central nervous system. *J Comp Neurol* 407(1):11–32. doi:10.1002/(SICI)1096-9861(19990428)407:1<11::AID-CNE2>3.0.CO;2-R
25. Vulchanova L, Riedl MS, Shuster SJ, Buell G, Surprenant A, North RA, Elde R (1997) Immunohistochemical study of the P2X2 and P2X3 receptor subunits in rat and monkey sensory neurons and their central terminals. *Neuropharmacology* 36(9):1229–1242
26. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G (1997) Tissue distribution of the P2X7 receptor. *Neuropharmacology* 36(9):1277–1283
27. Atkinson L, Batten TF, Deuchars J (2000) P2X(2) receptor immunoreactivity in the dorsal vagal complex and area postrema of the rat. *Neuroscience* 99(4):683–696
28. Deuchars SA, Atkinson L, Brooke RE, Musa H, Milligan CJ, Batten TF, Buckley NJ, Parson SH, Deuchars J (2001) Neuronal P2X7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. *J Neurosci* 21(18):7143–7152
29. Rubio ME, Soto F (2001) Distinct localization of P2X receptors at excitatory postsynaptic specializations. *J Neurosci* 21(2):641–653
30. Sim JA, Young MT, Sung HY, North RA, Surprenant A (2004) Reanalysis of P2X7 receptor expression in rodent brain. *J Neurosci* 24(28):6307–6314. doi:10.1523/JNEUROSCI.1469-04.2004
31. Tanaka J, Murate M, Wang CZ, Seino S, Iwanaga T (1996) Cellular distribution of the P2X4 ATP receptor mRNA in the brain and non-neuronal organs of rats. *Arch Histol Cytol* 59(5):485–490
32. Nakatsuka T, Gu JG (2001) ATP P2X receptor-mediated enhancement of glutamate release and evoked EPSCs in dorsal horn neurons of the rat spinal cord. *J Neurosci* 21(17):6522–6531
33. Watano T, Calvert JA, Vial C, Forsythe ID, Evans RJ (2004) P2X receptor subtype-specific modulation of excitatory and inhibitory synaptic inputs in the rat brainstem. *J Physiol* 558(Pt 3):745–757. doi:10.1113/jphysiol.2004.066845
34. Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA (2005) Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. *J Neurosci* 25(27):6286–6295. doi:10.1523/JNEUROSCI.0628-05.2005
35. Patti L, Raiteri L, Grilli M, Parodi M, Raiteri M, Marchi M (2006) P2X7 receptors exert a permissive role on the activation of release-enhancing presynaptic alpha7 nicotinic receptors co-existing on rat neocortex glutamatergic terminals. *Neuropharmacology* 50(6):705–713. doi:10.1016/j.neuropharm.2005.11.016
36. Jameson HS, Pinol RA, Mendelowitz D (2008) Purinergic P2X receptors facilitate inhibitory GABAergic and glycinergic neurotransmission to cardiac vagal neurons in the nucleus ambiguus. *Brain Res* 1224:53–62. doi:10.1016/j.brainres.2008.06.012
37. Illes P, Verkhratsky A, Burnstock G, Franke H (2012) P2X receptors and their roles in astroglia in the central and peripheral nervous system. *Neuroscientist*. doi:10.1177/1073858411418524
38. Duan S, Neary JT (2006) P2X7 receptors: properties and relevance to CNS function. *Glia* 54(7):738–746. doi:10.1002/glia.20397
39. Takenouchi T, Sekiyama K, Sekigawa A, Fujita M, Waragai M, Sugama S, Iwamaru Y, Kitani H, Hashimoto M (2010) P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. *Arch Immunol Ther Exp (Warsz)* 58(2):91–96. doi:10.1007/s00005-010-0069-y
40. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, Evans RJ (2000) Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. *Nature* 403(6765):86–89. doi:10.1038/47495
41. Vial C, Evans RJ (2000) P2X receptor expression in mouse urinary bladder and the requirement of P2X1 receptors for functional P2X receptor responses in the mouse urinary bladder smooth muscle. *Br J Pharmacol* 131(7):1489–1495. doi:10.1038/sj.bjp.0703720
42. Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C (2003) A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. *J Exp Med* 198(4):661–667. doi:10.1084/jem.20030144
43. Mahaut-Smith MP, Tolhurst G, Evans RJ (2004) Emerging roles for P2X1 receptors in platelet activation. *Platelets* 15(3):131–144. doi:10.1080/09537100410001682788
44. Calvert JA, Evans RJ (2004) Heterogeneity of P2X receptors in sympathetic neurons: contribution of neuronal P2X1 receptors revealed using knockout mice. *Mol Pharmacol* 65(1):139–148. doi:10.1124/mol.65.1.139
45. Lalo U, Pankratov Y, Wichert SP, Rossner MJ, North RA, Verkhratsky A (2008) P2X1 and P2X5 subunits form the functional P2X receptor in mouse cortical astrocytes. *J Neurosci* 28(21):5473–5480. doi:10.1523/JNEUROSCI.1149-08.2008
46. Rettinger J, Schmalzing G (2003) Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations. *J Gen Physiol* 121(5):451–461. doi:10.1085/jgp.200208730
47. Le KT, Paquet M, Nouel D, Babinski K, Seguela P (1997) Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system. *FEBS Lett* 418(1–2):195–199
48. Torres GE, Haines WR, Egan TM, Voigt MM (1998) Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. *Mol Pharmacol* 54(6):989–993
49. Haines WR, Torres GE, Voigt MM, Egan TM (1999) Properties of the novel ATP-gated ionotropic receptor composed of the P2X1 and P2X5 isoforms. *Mol Pharmacol* 56(4):720–727
50. Le KT, Boue-Grabot E, Archambault V, Seguela P (1999) Functional and biochemical evidence for heteromeric ATP-gated channels composed of P2X1 and P2X5 subunits. *J Biol Chem* 274(22):15415–15419



51. Duckwitz W, Hausmann R, Aschrafi A, Schmalzing G (2006) P2X5 subunit assembly requires scaffolding by the second transmembrane domain and a conserved aspartate. *J Biol Chem* 281(51):39561–39572. doi:10.1074/jbc.M606113200
52. Ase AR, Bernier LP, Blais D, Pankratov Y, Seguela P (2010) Modulation of heteromeric P2X1/5 receptors by phosphoinositides in astrocytes depends on the P2X1 subunit. *J Neurochem* 113(6):1676–1684. doi:10.1111/j.1471-4159.2010.06734.x
53. Kidd EJ, Grahames CB, Simon J, Michel AD, Barnard EA, Humphrey PP (1995) Localization of P2X purinoceptor transcripts in the rat nervous system. *Mol Pharmacol* 48(4):569–573
54. Pankratov Y, Castro E, Miras-Portugal MT, Krishtal O (1998) A purinergic component of the excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons of the rat hippocampus. *Eur J Neurosci* 10(12):3898–3902
55. Xiang Z, Bo X, Oglesby I, Ford A, Burnstock G (1998) Localization of ATP-gated P2X2 receptor immunoreactivity in the rat hypothalamus. *Brain Res* 813(2):390–397
56. Xiang Z, Burnstock G (2004) P2X2 and P2X3 purinoceptors in the rat enteric nervous system. *Histochem Cell Biol* 121(3):169–179. doi:10.1007/s00418-004-0620-1
57. Brass D, Grably MR, Bronstein-Sitton N, Gohar O, Meir A (2011) Using antibodies against P2Y and P2X receptors in purinergic signaling research. *Purinergic Signal*. doi:10.1007/s11302-011-9278-z
58. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS (2011) Activation and regulation of purinergic P2X receptor channels. *Pharmacol Rev* 63(3):641–683. doi:10.1124/pr.110.003129
59. Honore P, Kage K, Mikusa J, Watt AT, Johnston JF, Wyatt JR, Faltynek CR, Jarvis MF, Lynch K (2002) Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. *Pain* 99(1–2):11–19
60. Jarvis MF (2003) Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain. *Expert Opin Ther Targets* 7(4):513–522. doi:10.1517/14728222.7.4.513
61. Koshimizu TA, Ueno S, Tanoue A, Yanagihara N, Stojilkovic SS, Tsujimoto G (2002) Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains. *J Biol Chem* 277(49):46891–46899. doi:10.1074/jbc.M205274200
62. Wirkner K, Sperlagh B, Illes P (2007) P2X3 receptor involvement in pain states. *Mol Neurobiol* 36(2):165–183. doi:10.1007/s12035-007-0033-y
63. Trang T, Beggs S, Salter MW (2006) Purinoceptors in microglia and neuropathic pain. *Pflugers Arch* 452(5):645–652. doi:10.1007/s00424-006-0074-5
64. Gu JG, MacDermott AB (1997) Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. *Nature* 389(6652):749–753. doi:10.1038/39639
65. Vulchanova L, Riedl MS, Shuster SJ, Stone LS, Hargreaves KM, Buell G, Surprenant A, North RA, Elde R (1998) P2X3 is expressed by DRG neurons that terminate in inner lamina II. *Eur J Neurosci* 10(11):3470–3478
66. Nakatsuka T, Mena N, Ling J, Gu JG (2001) Depletion of substance P from rat primary sensory neurons by ATP, an implication of P2X receptor-mediated release of substance P. *Neuroscience* 107(2):293–300
67. Ford AP (2011) In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. *Purinergic Signal*. doi:10.1007/s11302-011-9271-6
68. Gum RJ, Wakefield B, Jarvis MF (2011) P2X receptor antagonists for pain management: examination of binding and physicochemical properties. *Purinergic Signal*. doi:10.1007/s11302-011-9272-5
69. Cheung KK, Chan WY, Burnstock G (2005) Expression of P2X purinoceptors during rat brain development and their inhibitory role on motor axon outgrowth in neural tube explant cultures. *Neuroscience* 133(4):937–945. doi:10.1016/j.neuroscience.2005.03.032
70. Buell G, Collo G, Rassendren F (1996) P2X receptors: an emerging channel family. *Eur J Neurosci* 8(10):2221–2228
71. Bo X, Kim M, Nori SL, Schoepfer R, Burnstock G, North RA (2003) Tissue distribution of P2X4 receptors studied with an ecto-domain antibody. *Cell Tissue Res* 313(2):159–165. doi:10.1007/s00441-003-0758-5
72. Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K (2009) Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. *Mol Pain* 5:28. doi:10.1186/1744-8069-5-28
73. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, Buell GN, Reeve AJ, Chessell IP, Rassendren F (2008) Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. *J Neurosci* 28(44):11263–11268. doi:10.1523/jneurosci.2308-08.2008
74. Ulmann L, Hirbec H, Rassendren F (2010) P2X4 receptors mediate PGE2 release by tissue-resident macrophages and initiate inflammatory pain. *EMBO J* 29(14):2290–2300. doi:10.1038/emboj.2010.126
75. Baxter AW, Choi SJ, Sim JA, North RA (2011) Role of P2X4 receptors in synaptic strengthening in mouse CA1 hippocampal neurons. *Eur J Neurosci* 34(2):213–220. doi:10.1111/j.1460-9568.2011.07763.x
76. Sim JA, Chaumont S, Jo J, Ulmann L, Young MT, Cho K, Buell G, North RA, Rassendren F (2006) Altered hippocampal synaptic potentiation in P2X4 knock-out mice. *J Neurosci* 26(35):9006–9009. doi:10.1523/jneurosci.2370-06.2006
77. Le KT, Babinski K, Seguela P (1998) Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor. *J Neurosci* 18(18):7152–7159
78. Nicke A, Kerschensteiner D, Soto F (2005) Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits. *J Neurochem* 92(4):925–933. doi:10.1111/j.1471-4159.2004.02939.x
79. Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD (2007) Evidence for functional P2X4/P2X7 heteromeric receptors. *Mol Pharmacol* 72(6):1447–1456. doi:10.1124/mol.107.035980
80. Guo W, Xu X, Gao X, Burnstock G, He C, Xiang Z (2008) Expression of P2X5 receptors in the mouse CNS. *Neuroscience* 156(3):673–692. doi:10.1016/j.neuroscience.2008.07.062
81. Guo W, Sun J, Xu X, Burnstock G, He C, Xiang Z (2009) P2X receptors are differentially expressed on vasopressin- and oxytocin-containing neurons in the supraoptic and paraventricular nuclei of rat hypothalamus. *Histochem Cell Biol* 131(1):29–41. doi:10.1007/s00418-008-0493-9
82. Kotnis S, Bingham B, Vasilyev DV, Miller SW, Bai Y, Yeola S, Chanda PK, Bowlby MR, Kaftan EJ, Samad TA, Whiteside GT (2010) Genetic and functional analysis of human P2X5 reveals a distinct pattern of exon 10 polymorphism with predominant expression of the nonfunctional receptor isoform. *Mol Pharmacol* 77(6):953–960. doi:10.1124/mol.110.063636
83. Robertson SJ, Ennion SJ, Evans RJ, Edwards FA (2001) Synaptic P2X receptors. *Curr Opin Neurobiol* 11(3):378–386
84. Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. *Int Rev Cytol* 240:31–304. doi:10.1016/s0074-7696(04)40002-3
85. da Silva RL, Resende RR, Ulrich H (2007) Alternative splicing of P2X6 receptors in developing mouse brain and during in vitro neuronal differentiation. *Exp Physiol* 92(1):139–145. doi:10.1113/expphysiol.2006.921304



86. Jones CA, Vial C, Sellers LA, Humphrey PP, Evans RJ, Chessell IP (2004) Functional regulation of P2X6 receptors by N-linked glycosylation: identification of a novel alpha beta-methylene ATP-sensitive phenotype. *Mol Pharmacol* 65(4):979–985. doi:10.1124/mol.65.4.979
87. Ormond SJ, Barrera NP, Qureshi OS, Henderson RM, Edwardson JM, Murrell-Lagnado RD (2006) An uncharged region within the N terminus of the P2X6 receptor inhibits its assembly and exit from the endoplasmic reticulum. *Mol Pharmacol* 69(5):1692–1700. doi:10.1124/mol.105.020404
88. Egan TM, Cox JA, Voigt MM (2004) Molecular structure of P2X receptors. *Curr Top Med Chem* 4(8):821–829
89. Yu Q, Zhao Z, Sun J, Guo W, Fu J, Burnstock G, He C, Xiang Z (2010) Expression of P2X6 receptors in the enteric nervous system of the rat gastrointestinal tract. *Histochem Cell Biol* 133(2):177–188. doi:10.1007/s00418-009-0659-0
90. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K (2007) The role of the purinergic P2X7 receptor in inflammation. *J Inflamm (Lond)* 4(5). doi:10.1186/1476-9255-4-5
91. Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1 $\beta$  release by the ATP-gated P2X7 receptor. *EMBO J* 25(21):5071–5082. doi:10.1038/sj.emboj.7601378[doi]
92. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. *J Immunol* 176(7):3877–3883
93. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* 272(5262):735–738
94. Ballerini P, Rathbone MP, Di Iorio P, Renzetti A, Giuliani P, D'Alimonte I, Trubiani O, Caciagli F, Ciccarelli R (1996) Rat astroglial P2Z (P2X7) receptors regulate intracellular calcium and purine release. *NeuroReport* 7(15–17):2533–2537
95. Brandle U, Guenther E, Irrle C, Wheeler-Schilling TH (1998) Gene expression of the P2X receptors in the rat retina. *Brain Res Mol Brain Res* 59(2):269–272
96. Gonzalez FA, Ahmed AH, Lustig KD, Erb L, Weisman GA (1989) Permeabilization of transformed mouse fibroblasts by 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate and the desensitization of the process. *J Cell Physiol* 139(1):109–115. doi:10.1002/jcp.1041390116
97. Erb L, Lustig KD, Ahmed AH, Gonzalez FA, Weisman GA (1990) Covalent incorporation of 3'-O-(4-benzoyl)benzoyl-ATP into a P2 purinoceptor in transformed mouse fibroblasts. *J Biol Chem* 265(13):7424–7431
98. Schulze-Lohoff E, Hugo C, Rost S, Arnold S, Gruber A, Brune B, Sterzel RB (1998) Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. *Am J Physiol* 275(6 Pt 2):F962–F971
99. Morelli A, Chiozzzi P, Chiesa A, Ferrari D, Sanz JM, Falzoni S, Pinton P, Rizzuto R, Olson MF, Di Virgilio F (2003) Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. *Mol Biol Cell* 14(7):2655–2664. doi:10.1091/mbc.02-04-0061
100. Verhoef PA, Estacion M, Schilling W, Dubyak GR (2003) P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. *J Immunol* 170(11):5728–5738
101. Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI (2004) P2X7 receptor-mediated apoptosis of human cervical epithelial cells. *Am J Physiol Cell Physiol* 287(5):C1349–C1358. doi:10.1152/ajpcell.00256.2004
102. Adinolfi E, Pizzirani C, Idzko M, Panther E, Norgauer J, Di Virgilio F, Ferrari D (2005) P2X7 receptor: death or life? *Purinergic Signal* 1(3):219–227. doi:10.1007/s11302-005-6322-x
103. Roger S, Pelegrin P, Surprenant A (2008) Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. *J Neurosci* 28(25):6393–6401. doi:10.1523/JNEUROSCI.0696-08.2008
104. Steinberg TH, Silverstein SC (1987) Extracellular ATP<sup>4-</sup> promotes cation fluxes in the J774 mouse macrophage cell line. *J Biol Chem* 262(7):3118–3122
105. Weisman GA, De BK, Pritchard RS (1989) Ionic dependence of the extracellular ATP-induced permeabilization of transformed mouse fibroblasts: role of plasma membrane activities that regulate cell volume. *J Cell Physiol* 138(2):375–383. doi:10.1002/jcp.1041380221
106. Hickman SE, Semrad CE, Silverstein SC (1996) P2Z purinoceptors. *CIBA Found Symp* 198:71–83, discussion 83–90
107. Atkinson L, Batten TF, Moores TS, Varoqui H, Erickson JD, Deuchars J (2004) Differential co-localisation of the P2X7 receptor subunit with vesicular glutamate transporters VGLUT1 and VGLUT2 in rat CNS. *Neuroscience* 123(3):761–768
108. Gordon GR, Baimoukhametova DV, Hewitt SA, Rajapaksha WR, Fisher TE, Bains JS (2005) Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. *Nat Neurosci* 8(8):1078–1086. doi:10.1038/nn1498
109. Kong Q, Wang M, Liao Z, Camden JM, Yu S, Simonyi A, Sun GY, Gonzalez FA, Erb L, Seye CI, Weisman GA (2005) P2X7 nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons. *Purinergic Signal* 1(4):337–347. doi:10.1007/s11302-005-7145-5
110. Sugiyama T, Oku H, Shibata M, Fukuhara M, Yoshida H, Ikeda T (2010) Involvement of P2X7 receptors in the hypoxia-induced death of rat retinal neurons. *Invest Ophthalmol Vis Sci* 51(6):3236–3243. doi:10.1167/iov.09-4192
111. Hide I, Tanaka M, Inoue A, Nakajima K, Kohsaka S, Inoue K, Nakata Y (2000) Extracellular ATP triggers tumor necrosis factor- $\alpha$  release from rat microglia. *J Neurochem* 75(3):965–972
112. Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y (2004) Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. *J Neurosci* 24(1):1–7. doi:10.1523/JNEUROSCI.3792-03.2004
113. Ballerini P, Ciccarelli R, Caciagli F, Rathbone MP, Werstliuk ES, Traversa U, Buccella S, Giuliani P, Jang S, Nargi E, Visini D, Santavenere C, Di Iorio P (2005) P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes. *Int J Immunopathol Pharmacol* 18(3):417–430
114. Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Inoue K (2009) Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. *J Neurochem* 108(1):115–125. doi:10.1111/j.1471-4159.2008.05744.x
115. Cavaliere F, Amadio S, Sancesario G, Bernardi G, Volonte C (2004) Synaptic P2X7 and oxygen/glucose deprivation in organotypic hippocampal cultures. *J Cereb Blood Flow Metab* 24(4):392–398. doi:10.1097/00004647-200404000-00004
116. Franke H, Gunther A, Grosche J, Schmidt R, Rossner S, Reinhardt R, Faber-Zuschratter H, Schneider D, Illes P (2004) P2X7 receptor expression after ischemia in the cerebral cortex of rats. *J Neuropathol Exp Neurol* 63(7):686–699
117. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. *Pain* 114(3):386–396. doi:10.1016/j.pain.2005.01.002
118. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R (2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. *J Biol Chem* 278(15):13309–13317. doi:10.1074/jbc.M209478200

119. McLarnon JG, Ryu JK, Walker DG, Choi HB (2006) Upregulated expression of purinergic P2X7 receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. *J Neuropathol Exp Neurol* 65(11):1090–1097. doi:10.1097/01.jnen.0000240470.97295.d3
120. Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, Gomez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, Lucas JJ (2009) Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. *FASEB J* 23(6):1893–1906. doi:10.1096/fj.08-122275
121. Nguyen T, Erb L, Weisman GA, Marchese A, Heng HH, Garrad RC, George SR, Turner JT, O'Dowd BF (1995) Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene. *J Biol Chem* 270(52):30845–30848
122. Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA (1995) Site-directed mutagenesis of P<sub>2U</sub> purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. *J Biol Chem* 270(9):4185–4188
123. Brinson AE, Harden TK (2001) Differential regulation of the uridine nucleotide-activated P2Y<sub>4</sub> and P2Y<sub>6</sub> receptors. SER-333 and SER-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y<sub>4</sub> receptor. *J Biol Chem* 276(15):11939–11948. doi:10.1074/jbc.M009909200
124. Flores RV, Hernandez-Perez MG, Aquino E, Garrad RC, Weisman GA, Gonzalez FA (2005) Agonist-induced phosphorylation and desensitization of the P2Y<sub>2</sub> nucleotide receptor. *Mol Cell Biochem* 280(1–2):35–45. doi:10.1007/s11010-005-8050-5
125. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol Rev* 58(3):281–341. doi:10.1124/pr.58.3.3
126. Erb L, Liao Z, Seye CI, Weisman GA (2006) P2 receptors: intracellular signaling. *Pflugers Arch* 452(5):552–562
127. Shaver SR (2001) P2Y receptors: biological advances and therapeutic opportunities. *Curr Opin Drug Discov Dev* 4(5):665–670
128. Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK, Jacobson KA (1997) A mutational analysis of residues essential for ligand recognition at the human P2Y<sub>1</sub> receptor. *Mol Pharmacol* 52(3):499–507
129. Jacobson KA, Hoffmann C, Kim YC, Camaioni E, Nandanan E, Jang SY, Guo DP, Ji XD, von Kugelgen I, Moro S, Ziganshin AU, Rychkov A, King BF, Brown SG, Wildman SS, Burnstock G, Boyer JL, Mohanram A, Harden TK (1999) Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. *Prog Brain Res* 120:119–132
130. Burnstock G, Dumsday B, Smythe A (1972) Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. *Br J Pharmacol* 44(3):451–461
131. Burnstock G (2009) Purinergic signalling: past, present and future. *Braz J Med Biol Res* 42(1):3–8
132. Neary JT, Zimmermann H (2009) Trophic functions of nucleotides in the central nervous system. *Trends Neurosci* 32(4):189–198. doi:10.1016/j.tins.2009.01.002
133. Burnstock G, Verkhratsky A (2010) Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. *Cell Death Dis* 1:e9. doi:10.1038/cddis.2009.11
134. Fumagalli M, Brambilla R, D'Ambrosi N, Volonté C, Matteoli M, Verderio C, Abbracchio MP (2003) Nucleotide-mediated calcium signaling in rat cortical astrocytes: role of P2X and P2Y receptors. *Glia* 43(3):218–303. doi:10.1002/glia.10248
135. Kreda SM, Seminario-Vidal L, Heusden C, Lazarowski ER (2008) Thrombin-promoted release of UDP-glucose from human astrocytoma cells. *Br J Pharmacol* 153(7):1528–1537. doi:10.1038/sj.bjp.0707692
136. Brandenburg LO, Jansen S, Wruck CJ, Lucius R, Pufe T (2010) Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways. *Mol Immunol* 47(10):1905–1913. doi:10.1016/j.molimm.2010.03.012
137. Lenz G, Gottfried C, Luo Z, Avruch J, Rodnight R, Nie WJ, Kang Y, Neary JT (2000) P2Y purinoceptor subtypes recruit different mek activators in astrocytes. *Br J Pharmacol* 129(5):927–936. doi:10.1038/sj.bjp.0703138
138. Jacques-Silva MC, Rodnight R, Lenz G, Liao Z, Kong Q, Tran M, Kang Y, Gonzalez FA, Weisman GA, Neary JT (2004) P2X7 receptors stimulate AKT phosphorylation in astrocytes. *Br J Pharmacol* 141(7):1106–1117. doi:10.1038/sj.bjp.0705685
139. Espada S, Ortega F, Molina-Jijón E, Rojo AI, Pérez-Sen R, Pedraza-Chaverri J, Miras-Portugal MT, Cuadrado A (2010) The purinergic P2Y<sub>13</sub> receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. *Free Radic Biol Med* 49(3):416–426. doi:10.1016/j.freeradbiomed.2010.04.031
140. Köles L, Leichsenring A, Rubini P, Illes P (2011) P2 receptor signaling in neurons and glial cells of the central nervous system. *Adv Pharmacol* 61:441–493. doi:10.1016/B978-0-12-385526-8.00014-X
141. Rodrigues RJ, Almeida T, de Mendonça A, Cunha RA (2006) Interaction between P2X and nicotinic acetylcholine receptors in glutamate nerve terminals of the rat hippocampus. *J Mol Neurosci* 30(1–2):173–176. doi:10.1385/JMN:30:1:173
142. Sperlág B, Illes P (2007) Purinergic modulation of microglial cell activation. *Purinergic Signal* 3(1–2):117–127. doi:10.1007/s11302-006-9043-x
143. Fischer W, Krügel U (2007) P2Y receptors: focus on structural, pharmacological and functional aspects in the brain. *Curr Med Chem* 14(23):2429–2455
144. Simon J, Webb TE, Barnard EA (1997) Distribution of [35 S]dATP  $\alpha$  S binding sites in the adult rat neuraxis. *Neuropharmacology* 36(9):1243–1251
145. Moore D, Chambers J, Waldvogel H, Faull R, Emson P (2000) Regional and cellular distribution of the P2Y<sub>1</sub> purinergic receptor in the human brain: striking neuronal localisation. *J Comp Neurol* 421(3):374–384. doi:10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z
146. Morán-Jiménez MJ, Matute C (2000) Immunohistochemical localization of the P2Y<sub>1</sub> purinergic receptor in neurons and glial cells of the central nervous system. *Brain Res Mol Brain Res* 78(1–2):50–58
147. Simon J, Webb TE, King BF, Burnstock G, Barnard EA (1995) Characterisation of a recombinant P2Y purinoceptor. *Eur J Pharmacol* 291(3):281–289
148. Fujita T, Tozaki-Saitoh H, Inoue K (2009) P2Y<sub>1</sub> receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. *Glia* 57(3):244–257. doi:10.1002/glia.20749
149. Gotsch U, Borges E, Bosse R, Boggemeyer E, Simon M, Mossmann H, Vestweber D (1997) VE-cadherin antibody accelerates neutrophil recruitment in vivo. *J Cell Sci* 110(Pt 5):583–588
150. Bianco F, Fumagalli M, Pravettoni E, D'Ambrosi N, Volonté C, Matteoli M, Abbracchio MP, Verderio C (2005) Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. *Brain Res Brain Res Rev* 48(2):144–156. doi:10.1016/j.brainresrev.2004.12.004
151. Mishra SK, Braun N, Shukla V, Füllgrabe M, Schomerus C, Korf HW, Gachet C, Ikehara Y, Sévigny J, Robson SC, Zimmermann H (2006) Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. *Development* 133(4):675–684. doi:10.1242/dev.02233

152. Sanada M, Yasuda H, Omatsu-Kanbe M, Sango K, Isono T, Matsuura H, Kikkawa R (2002) Increase in intracellular  $\text{Ca}^{2+}$  and calcitonin gene-related peptide release through metabotropic P2Y receptors in rat dorsal root ganglion neurons. *Neuroscience* 111(2):413–422
153. Ruan HZ, Burnstock G (2003) Localisation of P2Y<sub>1</sub> and P2Y<sub>4</sub> receptors in dorsal root, nodose and trigeminal ganglia of the rat. *Histochem Cell Biol* 120(5):415–426. doi:10.1007/s00418-003-0579-3
154. Kobayashi K, Fukuoka T, Yamanaka H, Iyamanaka H, Dai Y, Obata K, Tokunaga A, Noguchi K (2006) Neurons and glial cells differentially express P2Y receptor mRNAs in the rat dorsal root ganglion and spinal cord. *J Comp Neurol* 498(4):443–454. doi:10.1002/cne.21066
155. Gerevich Z, Müller C, Illes P (2005) Metabotropic P2Y<sub>1</sub> receptors inhibit P2X<sub>3</sub> receptor-channels in rat dorsal root ganglion neurons. *Eur J Pharmacol* 521(1–3):34–38. doi:10.1016/j.ejphar.2005.08.001
156. Franke H, Illes P (2006) Involvement of P2 receptors in the growth and survival of neurons in the CNS. *Pharmacol Ther* 109(3):297–324. doi:10.1016/j.pharmthera.2005.06.002
157. Inoue K (2008) Purinergic systems in microglia. *Cell Mol Life Sci* 65(19):3074–3080. doi:10.1007/s00018-008-8210-3
158. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhali A, Inoue Y, Woehrle T, Zhang Q, Hauser C, Junger WG (2010) Purinergic signaling: a fundamental mechanism in neutrophil activation. *Sci Signal* 3(125):ra45. doi:10.1126/scisignal.2000549
159. Turner JT, Weisman GA, Camden JM (1997) Upregulation of P2Y<sub>2</sub> nucleotide receptors in rat salivary gland cells during short-term culture. *Am J Physiol* 273(3 Pt 1):C1100–C1107
160. Koshiba M, Apasov S, Sverdllov V, Chen P, Erb L, Turner JT, Weisman GA, Sitkovsky MV (1997) Transient up-regulation of P2Y<sub>2</sub> nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes. *Proc Natl Acad Sci U S A* 94(3):831–836
161. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner JT, Sturek M, Gonzalez FA, Weisman GA (2002) Functional P2Y<sub>2</sub> nucleotide receptors mediate uridine 5'-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. *Circulation* 106(21):2720–2726
162. Shen J, Seye CI, Wang M, Weisman GA, Wilden PA, Sturek M (2004) Cloning, up-regulation, and mitogenic role of porcine P2Y<sub>2</sub> receptor in coronary artery smooth muscle cells. *Mol Pharmacol* 66(5):1265–1274. doi:10.1124/mol.104.002642
163. Schrader AM, Camden JM, Weisman GA (2005) P2Y<sub>2</sub> nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjogren's syndrome. *Arch Oral Biol* 50(6):533–540. doi:10.1016/j.archoralbio.2004.11.005
164. Rodríguez-Zayas AE, Torrado AI, Miranda JD (2010) P2Y<sub>2</sub> receptor expression is altered in rats after spinal cord injury. *Int J Dev Neurosci* 28(6):413–421. doi:10.1016/j.ijdevneu.2010.07.001
165. Franke H, Krügel U, Grosche J, Heine C, Härtig W, Allgaier C, Illes P (2004) P2Y receptor expression on astrocytes in the nucleus accumbens of rats. *Neuroscience* 127(2):431–441. doi:10.1016/j.neuroscience.2004.05.003
166. Degagne E, Grbic DM, Dupuis AA, Lavoie EG, Langlois C, Jain N, Weisman GA, Sevigny J, Gendron FP (2009) P2Y<sub>2</sub> receptor transcription is increased by NF- $\kappa$ B and stimulates cyclooxygenase-2 expression and PGE<sub>2</sub> released by intestinal epithelial cells. *J Immunol* 183(7):4521–4529
167. Wullaert A, Bonnet MC, Pasparakis M (2011) NF- $\kappa$ B in the regulation of epithelial homeostasis and inflammation. *Cell Res* 21(1):146–158. doi:10.1038/cr.2010.175
168. Soltoff SP (1998) Related adhesion focal tyrosine kinase and the epidermal growth factor receptor mediate the stimulation of mitogen-activated protein kinase by the G-protein-coupled P2Y<sub>2</sub> receptor. Phorbol ester or  $[\text{Ca}^{2+}]_i$  elevation can substitute for receptor activation. *J Biol Chem* 273(36):23110–23117
169. Soltoff SP, Avraham H, Avraham S, Cantley LC (1998) Activation of P2Y<sub>2</sub> receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. *J Biol Chem* 273(5):2653–2660
170. Seye CI, Yu N, Gonzalez FA, Erb L, Weisman GA (2004) The P2Y<sub>2</sub> nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). *J Biol Chem* 279(34):35679–35686
171. Ratchford AM, Baker OJ, Camden JM, Rikka S, Petris MJ, Seye CI, Erb L, Weisman GA (2010) P2Y<sub>2</sub> nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. *J Biol Chem* 285(10):7545–7555. doi:10.1074/jbc.M109.078170
172. Erb L, Liu J, Ockerhausen J, Kong Q, Garrad RC, Griffin K, Neal C, Krugh B, Santiago-Perez LI, Gonzalez FA, Gresham HD, Turner JT, Weisman GA (2001) An RGD sequence in the P2Y<sub>2</sub> receptor interacts with  $\alpha_v\beta_3$  integrins and is required for G<sub>o</sub>-mediated signal transduction. *J Cell Biol* 153(3):491–501
173. Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA, Erb L (2005) The P2Y<sub>2</sub> nucleotide receptor interacts with  $\alpha_v$  integrins to activate G<sub>o</sub> and induce cell migration. *J Biol Chem* 280(47):39050–39057. doi:10.1074/jbc.M504819200
174. Liao Z, Seye CI, Weisman GA, Erb L (2007) The P2Y<sub>2</sub> nucleotide receptor requires interaction with  $\alpha_v$  integrins to access and activate G<sub>12</sub>. *J Cell Sci* 120(Pt 9):1654–1662. doi:10.1242/jcs.03441
175. Xu J, Wang F, Van Keymeulen A, Herzmark P, Straight A, Kelly K, Takuwa Y, Sugimoto N, Mitchison T, Bourne HR (2003) Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. *Cell* 114(2):201–214
176. Jang DH, Han JH, Lee SH, Lee YS, Park H, Kim H, Kaang BK (2005) Cofilin expression induces cofilin-actin rod formation and disrupts synaptic structure and function in Aplysia synapses. *Proc Natl Acad Sci U S A* 102(44):16072–16077. doi:10.1073/pnas.0507675102
177. Yu N, Erb L, Shivaji R, Weisman GA, Seye CI (2008) Binding of the P2Y<sub>2</sub> nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. *Circ Res* 102(5):581–588. doi:10.1161/CIRCRESAHA.107.162271
178. Norambuena A, Palma F, Poblete MI, Donoso MV, Pardo E, González A, Huidobro-Toro JP (2010) UTP controls cell surface distribution and vasomotor activity of the human P2Y<sub>2</sub> receptor through an epidermal growth factor receptor-transregulated mechanism. *J Biol Chem* 285(5):2940–2950. doi:10.1074/jbc.M109.081166
179. Xie Z, Smith CJ, Van Eldik LJ (2004) Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. *Glia* 45(2):170–179. doi:10.1002/glia.10314
180. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer's disease. *Arch Pharm Res* 33(10):1539–1556. doi:10.1007/s12272-010-1006-7
181. Pooler AM, Guez DH, Benedictus R, Wurtman RJ (2005) Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. *Neuroscience* 134(1):207–214. doi:10.1016/j.neuroscience.2005.03.050
182. Bousein C, Zacharias R, Färber K, Pavlovic S, Hanisch UK, Kettenmann H (2003) Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation in vitro. *Eur J Neurosci* 17(11):2267–2276
183. Kim HJ, Ajit D, Peterson TS, Wang Y, Camden JM, Wood WG, Sun GY, Erb LE, Petris M, Weisman GA (2012) Nucleotides released from fibrillar A $\beta_{1-42}$ -treated microglial cells increase cell migration and fibrillar A $\beta_{1-42}$  uptake through P2Y<sub>2</sub> receptor activation. *J Neurochem*. doi:10.1111/j.1471-4159.2012.07700.x
184. Halassa MM, Fellin T, Haydon PG (2009) Tripartite synapses: roles for astrocytic purines in the control of synaptic physiology and behavior. *Neuropharmacology* 57(4):343–346. doi:10.1016/j.neuropharm.2009.06.031



185. Chorna NE, Santiago-Perez LI, Erb L, Seye CI, Neary JT, Sun GY, Weisman GA, Gonzalez FA (2004) P2Y receptors activate neuroprotective mechanisms in astrocytic cells. *J Neurochem* 91(1):119–132
186. Webb TE, Henderson DJ, Roberts JA, Barnard EA (1998) Molecular cloning and characterization of the rat P2Y<sub>4</sub> receptor. *J Neurochem* 71(4):1348–1357
187. Brunschweiler A, Muller CE (2006) P2 receptors activated by uracil nucleotides—an update. *Curr Med Chem* 13(3):289–312
188. Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H (2009) Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signal* 5(1):75–89. doi:10.1007/s11302-008-9106-2
189. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock PR (2001) Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. *Biochim Biophys Acta* 1521(1–3):107–119
190. Simard M, Arcuino G, Takano T, Liu QS, Nedergaard M (2003) Signaling at the gliovascular interface. *J Neurosci* 23(27):9254–9262
191. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignoto G (2003) Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. *Nat Neurosci* 6(1):43–50. doi:10.1038/nn980
192. Communi D, Parmentier M, Boeynaems JM (1996) Cloning, functional expression and tissue distribution of the human P2Y<sub>6</sub> receptor. *Biochem Biophys Res Commun* 222(2):303–308
193. Calvert JA, Atterbury-Thomas AE, Leon C, Forsythe ID, Gachet C, Evans RJ (2004) Evidence for P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>6</sub> and atypical UTP-sensitive receptors coupled to rises in intracellular calcium in mouse cultured superior cervical ganglion neurons and glia. *Br J Pharmacol* 143(5):525–532. doi:10.1038/sj.bjp.0705959
194. Bennett GC, Ford AP, Smith JA, Emmett CJ, Webb TE, Boarder MR (2003) P2Y receptor regulation of cultured rat cerebral cortical cells: calcium responses and mRNA expression in neurons and glia. *Br J Pharmacol* 139(2):279–288. doi:10.1038/sj.bjp.0705242
195. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K (2007) UDP acting at P2Y<sub>6</sub> receptors is a mediator of microglial phagocytosis. *Nature* 446(7139):1091–1095
196. Liu GD, Ding JQ, Xiao Q, Chen SD (2009) P2Y<sub>6</sub> receptor and immunoinflammation. *Neurosci Bull* 25(3):161–164
197. Communi D, Robaye B, Boeynaems JM (1999) Pharmacological characterization of the human P2Y<sub>11</sub> receptor. *Br J Pharmacol* 128(6):1199–1206. doi:10.1038/sj.bjp.0702909
198. Volonté C, Amadio S, D'Ambrosi N, Colpi M, Burnstock G (2006) P2 receptor web: complexity and fine-tuning. *Pharmacol Ther* 112(1):264–280. doi:10.1016/j.pharmthera.2005.04.012
199. Vaughan KR, Stokes L, Prince LR, Marriott HM, Meis S, Kassack MU, Bingle CD, Sabroe I, Surprenant A, Whyte MK (2007) Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y<sub>11</sub> receptor. *J Immunol* 179(12):8544–8553
200. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurdan P, Nurdan A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. *Nature* 409(6817):202–207
201. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM (2003) ADP receptors—targets for developing antithrombotic agents. *Curr Pharm Des* 9(28):2303–2316
202. Carrasquero LM, Delicado EG, Jiménez AI, Pérez-Sen R, Miras-Portugal MT (2005) Cerebellar astrocytes co-express several ADP receptors. Presence of functional P2Y<sub>13</sub>-like receptors. *Purinergic Signal* 1(2):153–159. doi:10.1007/s11302-005-6211-3
203. Sasaki Y, Hoshi M, Akazawa C, Nakamura Y, Tsuzuki H, Inoue K, Kohsaka S (2003) Selective expression of Gi/o-coupled ATP receptor P2Y<sub>12</sub> in microglia in rat brain. *Glia* 44(3):242–250. doi:10.1002/glia.10293
204. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D (2006) The P2Y<sub>12</sub> receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* 9(12):1512–1519. doi:10.1038/nn1805
205. Amadio S, Tramini G, Martorana A, Viscomi MT, Sancesario G, Bernardi G, Volonté C (2006) Oligodendrocytes express P2Y<sub>12</sub> metabotropic receptor in adult rat brain. *Neuroscience* 141(3):1171–1180. doi:10.1016/j.neuroscience.2006.05.058
206. Marteau F, Le Poul E, Communi D, Labouret C, Savi P, Boeynaems JM, Gonzalez NS (2003) Pharmacological characterization of the human P2Y<sub>13</sub> receptor. *Mol Pharmacol* 64(1):104–112. doi:10.1124/mol.64.1.104
207. Burnstock G (2006) Purinergic signalling. *Br J Pharmacol* 147(Suppl 1):S172–S181
208. Communi D, Govaerts C, Parmentier M, Boeynaems JM (1997) Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. *J Biol Chem* 272(51):31969–31973
209. Jiménez E, Zafra F, Pérez-Sen R, Delicado EG, Miras-Portugal MT, Aragón C, López-Corcuera B (2011) P2Y purinergic regulation of the glycine neurotransmitter transporters. *J Biol Chem* 286(12):10712–10724. doi:10.1074/jbc.M110.167056
210. Gomeza J, Ohno K, Hülsmann S, Arnsen W, Eulenburg V, Richter DW, Laube B, Betz H (2003) Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality. *Neuron* 40(4):797–806
211. Ortega F, Pérez-Sen R, Miras-Portugal MT (2008) Gi-coupled P2Y-ADP receptor mediates GSK-3 phosphorylation and  $\beta$ -catenin nuclear translocation in granule neurons. *J Neurochem* 104(1):62–73. doi:10.1111/j.1471-4159.2007.05021.x
212. Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson S, Livi GP (2000) A G protein-coupled receptor for UDP-glucose. *J Biol Chem* 275(15):10767–10771
213. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA, Burnstock G (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y<sub>14</sub> receptor) adds diversity to the P2Y receptor family. *Trends Pharmacol Sci* 24(2):52–55
214. Burnstock G (2006) Historical review: ATP as a neurotransmitter. *Trends Pharmacol Sci* 27(3):166–176
215. Lazarowski ER, Shea DA, Boucher RC, Harden TK (2003) Release of cellular UDP-glucose as a potential extracellular signaling molecule. *Mol Pharmacol* 63(5):1190–1197
216. Skelton L, Cooper M, Murphy M, Platt A (2003) Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y<sub>14</sub>) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose. *J Immunol* 171(4):1941–1949
217. Di Virgilio F (2007) Liaisons dangereuses: P2X<sub>7</sub> and the inflammasome. *Trends Pharmacol Sci* 28(9):465–472. doi:10.1016/j.tips.2007.07.002
218. Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* 10(3):210–215. doi:10.1038/nri2725
219. Pfeiffer ZA, Aga M, Prabhu U, Watters JJ, Hall DJ, Bertics PJ (2004) The nucleotide receptor P2X<sub>7</sub> mediates actin reorganization and membrane blebbing in RAW 264.7 macrophages via p38 MAP kinase and Rho. *J Leukoc Biol* 75(6):1173–1182. doi:10.1189/jlb.1203648



220. Potucek YD, Crain JM, Watters JJ (2006) Purinergic receptors modulate MAP kinases and transcription factors that control microglial inflammatory gene expression. *Neurochem Int* 49(2):204–214. doi:10.1016/j.neuint.2006.04.005
221. Lenertz LY, Gavala ML, Hill LM, Bertics PJ (2009) Cell signaling via the P2X7 nucleotide receptor: linkage to ROS production, gene transcription, and receptor trafficking. *Purinergic Signal* 5(2):175–187. doi:10.1007/s11302-009-9133-7
222. Skaper SD, Debetto P, Giusti P (2009) The P2X7 purinergic receptor: from physiology to neurological disorders. *FASEB J* 24(2):337–345. doi:10.1096/fj.09-138883
223. Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K (2010) P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. *J Neurochem* 114(3):810–819. doi:10.1111/j.1471-4159.2010.06809.x
224. Bodin P, Burnstock G (2001) Purinergic signalling: ATP release. *Neurochem Res* 26(8–9):959–969
225. Fields RD (2011) Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. *Semin Cell Dev Biol* 22(2):214–219. doi:10.1016/j.semcdb.2011.02.009
226. Sanz JM, Chiozzi P, Ferrari D, Colaianna M, Idzko M, Falzoni S, Fellin R, Trabace L, Di Virgilio F (2009) Activation of microglia by amyloid  $\beta$  requires P2X7 receptor expression. *J Immunol* 182(7):4378–4385. doi:10.4049/jimmunol.0803612[doi]
227. El Khoury J, Luster AD (2008) Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. *Trends Pharmacol Sci* 29(12):626–632. doi:10.1016/j.tips.2008.08.004
228. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. *J Immunol* 168(12):6436–6445
229. McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, Wismer CT, Zhu CZ, Gauvin DM, Fabiyi AC, Honore P, Gregg RJ, Kort ME, Nelson DW, Carroll WA, Marsh K, Faltynek CR, Jarvis MF (2007) P2X7-related modulation of pathological nociception in rats. *Neuroscience* 146(4):1817–1828. doi:10.1016/j.neuroscience.2007.03.035
230. Lucattelli M, Cicko S, Muller T, Lommatzsch M, De Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, Durk T, Zissel G, Sorichter S, Ferrari D, Di Virgilio F, Virchow JC, Lungarella G, Idzko M (2011) P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. *Am J Respir Cell Mol Biol* 44(3):423–429. doi:10.1165/rcmb.2010-0038OC
231. Friedle SA, Curet MA, Watters JJ (2010) Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. *Recent Pat CNS Drug Discov* 5(1):35–45
232. Arulkumaran N, Unwin RJ, Tam FW (2011) A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. *Expert Opin Investig Drugs* 20(7):897–915. doi:10.1517/13543784.2011.578068
233. Bamburg JR, Bloom GS (2009) Cytoskeletal pathologies of Alzheimer disease. *Cell Motil Cytoskeleton* 66(8):635–649. doi:10.1002/cm.20388
234. Arthur DB, Akassoglou K, Insel PA (2005) P2Y<sub>2</sub> receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation. *Proc Natl Acad Sci U S A* 102(52):19138–19143. doi:10.1073/pnas.0505913102
235. Arthur DB, Akassoglou K, Insel PA (2006) P2Y<sub>2</sub> and TrkA receptors interact with Src family kinase for neuronal differentiation. *Biochem Biophys Res Commun* 347(3):678–682. doi:10.1016/j.bbrc.2006.06.141
236. Grimm I, Messemer N, Stanke M, Gachet C, Zimmermann H (2009) Coordinate pathways for nucleotide and EGF signaling in cultured adult neural progenitor cells. *J Cell Sci* 122(Pt 14):2524–2533. doi:10.1242/jcs.044891
237. Arthur DB, Georgi S, Akassoglou K, Insel PA (2006) Inhibition of apoptosis by P2Y<sub>2</sub> receptor activation: novel pathways for neuronal survival. *J Neurosci* 26(14):3798–3804. doi:10.1523/JNEUROSCI.5338-05.2006
238. Walker DG, Kim SU, McGeer PL (1995) Complement and cytokine gene expression in cultured microglial derived from post-mortem human brains. *J Neurosci Res* 40(4):478–493. doi:10.1002/jnr.490400407
239. Sudo S, Tanaka J, Toku K, Desaki J, Matsuda S, Arai T, Sakanaka M, Maeda N (1998) Neurons induce the activation of microglial cells in vitro. *Exp Neurol* 154(2):499–510. doi:10.1006/exnr.1998.6911
240. Shlosberg D, Benifla M, Kaufer D, Friedman A (2010) Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury. *Nat Rev Neurol* 6(7):393–403. doi:10.1038/nrneurol.2010.74
241. Barreto GE, Gonzalez J, Torres Y, Morales L (2011) Astrocytic–neuronal crosstalk: implications for neuroprotection from brain injury. *Neurosci Res* 71(2):107–113. doi:10.1016/j.neures.2011.06.004
242. Takenouchi T, Sugama S, Iwamaru Y, Hashimoto M, Kitani H (2009) Modulation of the ATP-Induced release and processing of IL-1 $\beta$  in microglial cells. *Crit Rev Immunol* 29(4):335–345
243. Sugama S, Takenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H (2009) Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. *Inflamm Allergy Drug Targets* 8(4):277–284
244. Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N (2010) Astroglial networks: a step further in neuroglial and gliovascular interactions. *Nat Rev Neurosci* 11(2):87–99. doi:10.1038/nrn2757
245. Butt AM (2011) ATP: a ubiquitous gliotransmitter integrating neuron–glial networks. *Semin Cell Dev Biol* 22(2):205–213. doi:10.1016/j.semcdb.2011.02.023
246. Hamilton N, Vayro S, Kirchhoff F, Verkhratsky A, Robbins J, Gorecki DC, Butt AM (2008) Mechanisms of ATP- and glutamate-mediated calcium signaling in white matter astrocytes. *Glia* 56(7):734–749. doi:10.1002/glia.20649
247. Hamilton N, Vayro S, Wigley R, Butt AM (2010) Axons and astrocytes release ATP and glutamate to evoke calcium signals in NG2-glia. *Glia* 58(1):66–79. doi:10.1002/glia.20902
248. Burgos M, Neary JT, González FA (2007) P2Y<sub>2</sub> nucleotide receptors inhibit trauma-induced death of astrocytic cells. *J Neurochem* 103(5):1785–1800. doi:10.1111/j.1471-4159.2007.04872.x
249. Wang M, Kong Q, Gonzalez FA, Sun G, Erb L, Seye C, Weisman GA (2005) P2Y nucleotide receptor interaction with  $\alpha_v$  integrin mediates astrocyte migration. *J Neurochem* 95(3):630–640
250. D'Alimonte I, Ciccarelli R, Di Iorio P, Nargi E, Buccella S, Giuliani P, Rathbone MP, Jiang S, Caciagli F, Ballerini P (2007) Activation of P2X7 receptors stimulates the expression of P2Y<sub>2</sub> receptor mRNA in astrocytes cultured from rat brain. *Int J Immunopathol Pharmacol* 20(2):301–316
251. Chakfé Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, Seguela P (2002) ADP and AMP induce interleukin-1 $\beta$  release from microglial cells through activation of ATP-primed P2X7 receptor channels. *J Neurosci* 22(8):3061–3069
252. Choi HB, Ryu JK, Kim SU, McLarnon JG (2007) Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. *J Neurosci* 27(18):4957–4968. doi:10.1523/JNEUROSCI.5417-06.2007
253. Mingam R, De Smedt V, Amédée T, Bluthé RM, Kelley KW, Dantzer R, Layé S (2008) In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1  $\beta$  in the murine brain. *Brain Behav Immun* 22(2):234–244. doi:10.1016/j.bbi.2007.08.007

254. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. *Trends Neurosci* 19(8):312–318
255. Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. *Glia* 40(2):133–139. doi:10.1002/glia.10154
256. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M (2005) Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. *Mol Cell Neurosci* 29(3):381–393. doi:10.1016/j.mcn.2005.03.005
257. Turrin NP, Rivest S (2006) Tumor necrosis factor  $\alpha$  but not interleukin 1  $\beta$  mediates neuroprotection in response to acute nitric oxide excitotoxicity. *J Neurosci* 26(1):143–151. doi:10.1523/JNEUROSCI.4032-05.2006
258. Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. *J Neurosci* 27(10):2596–2605. doi:10.1523/JNEUROSCI.5360-06.2007
259. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat Med* 13(4):432–438. doi:10.1038/nm1555
260. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. *Science* 312(5778):1389–1392. doi:10.1126/science.1123511
261. Streit WJ (2006) Microglial senescence: does the brain's immune system have an expiration date? *Trends Neurosci* 29(9):506–510. doi:10.1016/j.tins.2006.07.001
262. Neumann H, Takahashi K (2007) Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. *J Neuroimmunol* 184(1–2):92–99. doi:10.1016/j.jneuroim.2006.11.032
263. Brown GC, Neher JJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. *Mol Neurobiol* 41(2–3):242–247. doi:10.1007/s12035-010-8105-9
264. Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K, Kohsaka S (2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. *J Neurosci* 21(6):1975–1982
265. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y<sub>2</sub> and A<sub>3</sub> receptors. *Science* 314(5806):1792–1795
266. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. *Nat Neurosci* 8(6):752–758. doi:10.1038/nn1472
267. Shigemoto-Mogami Y, Koizumi S, Tsuda M, Ohsawa K, Kohsaka S, Inoue K (2001) Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5. *J Neurochem* 78(6):1339–1349
268. Crain JM, Nikodemova M, Watters JJ (2009) Expression of P2 nucleotide receptors varies with age and sex in murine brain microglia. *J Neuroinflammation* 6:24. doi:10.1186/1742-2094-6-24
269. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature* 461(7261):282–286. doi:10.1038/nature08296
270. Rogers J, Lue LF (2001) Microglial chemotaxis, activation, and phagocytosis of amyloid  $\beta$ -peptide as linked phenomena in Alzheimer's disease. *Neurochem Int* 39(5–6):333–340
271. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim HC, Sargin S, Schön P, Schwab A, Hanley PJ (2010) Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. *Sci Signal* 3(132):ra55. doi:10.1126/scisignal.2000588
272. Ben Yebdri F, Kukulski F, Tremblay A, Sévigny J (2009) Concomitant activation of P2Y<sub>2</sub> and P2Y<sub>6</sub> receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. *Eur J Immunol* 39(10):2885–2894. doi:10.1002/eji.200939347
273. Kukulski F, Ben Yebdri F, Bahrami F, Fausther M, Tremblay A, Sévigny J (2010) Endothelial P2Y<sub>2</sub> receptor regulates LPS-induced neutrophil transendothelial migration in vitro. *Mol Immunol* 47(5):991–999. doi:10.1016/j.molimm.2009.11.020
274. Chung H, Brazil MI, Soe TT, Maxfield FR (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. *J Biol Chem* 274(45):32301–32308
275. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGF- $\beta$ 1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. *Nat Med* 7(5):612–618. doi:10.1038/87945
276. Pihlaja R, Koistinaho J, Malm T, Sikkilä H, Vainio S, Koistinaho M (2008) Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. *Glia* 56(2):154–163. doi:10.1002/glia.20599[doi]
277. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE (2009) Microglia mediate the clearance of soluble A $\beta$  through fluid phase macropinocytosis. *J Neurosci* 29(13):4252–4262. doi:10.1523/JNEUROSCI.5572-08.2009
278. Kong Y, Ruan L, Qian L, Liu X, Le Y (2010) Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. *J Neurosci* 30(35):11848–11857. doi:10.1523/JNEUROSCI.2985-10.2010
279. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Collo G, Buell G, Di Virgilio F (1997) ATP-mediated cytotoxicity in microglial cells. *Neuropharmacology* 36(9):1295–1301
280. Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D, Sanz JM, Venketaraman V, Baricordi OR (1998) Cytolytic P2X purinoceptors. *Cell Death Differ* 5(3):191–199. doi:10.1038/sj.cdd.4400341
281. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T (2010) Macrophages in Alzheimer's disease: the blood-borne identity. *J Neural Transm* 117(8):961–970. doi:10.1007/s00702-010-0422-7
282. Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. *Proc Natl Acad Sci U S A* 106(4):1261–1266. doi:10.1073/pnas.0805453106
283. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. *Neuron* 49(4):489–502. doi:10.1016/j.neuron.2006.01.022